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Abstract 
Benign prostatic hyperplasia (BPH) is one of the most common chronic urological 
diseases among elderly men. Proliferation of the prostate and contraction of 
prostate and urethral smooth muscles cause bladder outlet obstruction (BOO) and 
lower urinary tract symptoms (LUTS). Current pharmacotherapies such as alpha1-
adrenoceptor antagonists (α1-blockers), steroid 5α-reductase inhibitors, and type 5 
phosphodiesterase inhibitors for alleviating BOO, LUTS, particularly bladder 
storage symptoms, and prostate stromal cell proliferation are in need of 
improvement. 
Lysophosphatidic acid (LPA) is a simple phospholipid with diverse 
biological actions. However, the role of LPA and LPA receptors in the lower 
urinary tract remain poorly understood. This study investigated the role of LPA 
and the type 1 LPA receptor (LPA1), the most abundantly expressed LPA receptor 
subtype, in the regulation of the lower urinary tract using ASP6432 (potassium 1-
(2-{[3,5-dimethoxy-4-methyl-N-(3-phenylpropyl)benzamido]methyl}-1,3-
thiazole-4-carbonyl)-3-ethyl-2,2-dioxo-2λ6-diazathian-1-ide), a novel LPA1 
antagonist. 
ASP6432 exhibited potent and selective antagonistic activity against LPA1. 
ASP6432 dose-dependently inhibited LPA-induced urethral and prostate 
contractions. In anesthetized rats, ASP6432 decreased the urethral perfusion 
pressure (UPP) in the absence of exogenous LPA stimulation more potently than 
the α1-blocker tamsulosin. ASP6432 also suppressed LPA-induced human prostate 
stroma cell proliferation. These results suggest a pivotal role for LPA1 in the 
regulation of urethral tonus and prostate cell proliferation. 
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Because the reduction in UPP by ASP6432 suggests the importance of LPA1 
in maintaining urethral tonus, the effect of ASP6432 on UPP at the bladder filling 
phase (UPPbase) and the minimum UPP at the urine voiding phase (UPPnadir) was 
measured in anesthetized rats to evaluate the role of LPA1 during urine voiding. 
ASP6432 dose-dependently decreased UPPbase and UPPnadir. While tamsulosin 
reduced UPPbase, it did not change UPPnadir. To further investigate the potential of 
an LPA1 antagonist during voiding, the effect of ASP6432 on voiding dysfunction 
induced by the NO synthase inhibitor Nω-nitro-L-arginine methyl ester (L-
NAME) was evaluated. ASP6432 dose-dependently suppressed the L-NAME-
induced increase in post-void residual urine (PVR) and the decreased voiding 
efficiency (VE), neither of which were altered by tamsulosin. These results 
suggest that LPA1 may play a significant role in regulating urethral tonus during 
urine voiding, and that ASP6432 has the potential to improve voiding dysfunction. 
One significant unmet need of current pharmacotherapies for BPH is in the 
improvement of urine storage symptoms. As the role of LPA and LPA1 in the 
regulation of bladder function is unknown in vivo, the effect of LPA and ASP6432 
on the micturition reflex was investigated. Intravenous infusion of LPA caused 
urinary frequency characterized by decreases in the micturition interval (MI) and 
threshold pressure (TP). ASP6432 dose-dependently inhibited the LPA-induced 
decrease in MI. To explore the potential of improving urinary frequency by 
suppressing LPA1, the effect of ASP6432 on urinary frequency induced by L-
NAME was evaluated. ASP6432 reversed the L-NAME-induced decrease in MI. 
These findings suggest that LPA is capable of modulating urinary frequency in 
vivo via LPA1, and that LPA1 antagonists can improve urinary frequency. 
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The present study indicates that ASP6432 had potent and selective 
antagonistic activity against LPA1, and suppressed not only LPA-induced urethral 
contractions but also urethral pressure in the absence of external LPA stimulation 
to a greater extent than tamsulosin. In addition, ASP6432 suppressed urethral 
pressure during urine voiding and L-NAME-induced voiding dysfunction, neither 
of which were affected by tamsulosin. Moreover, ASP6432 inhibited the LPA-
induced proliferation of human prostate stromal cells. Further, ASP6432 improved 
both LPA- and L-NAME-induced urinary frequency. These findings demonstrate 
for the first time a significant role for LPA1 in the regulation of the lower urinary 
tract, and the potential of ASP6432 as a novel therapy for the treatment of BPH by 
relaxing the urethra, ameliorating bladder overactivity, and suppressing prostate 
stromal cell proliferation.  
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Abbreviations 
AUC  area under the curve 
BOO  benign outlet obstruction 
BP  baseline pressure 
BPE  benign prostatic enlargement 
BPH  benign prostatic hyperplasia 
BSA  bovine serum albumin 
CMG  cystometry 
HFOs  high frequency oscillations 
IUP  intraurethral pressure 
iv  intravenous 
IVP  intravesical pressure 
L-NAME Nω-nitro-L-arginine methyl ester 
LPA  lysophosphatidic acid 
LPA1  type 1 lysophosphatidic acid receptor 
LUTS  lower urinary tract symptoms 
max IVP maximum intravesical pressure 
MI  micturition interval 
NO  nitric oxide 
NOS  nitric oxide synthase 
PDE  phosphodiesterase 
PPAR  peroxisome proliferator activated receptor 
PVR  post-void residual urine 
TP  threshold pressure 
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TRP  transient receptor potential 
UAB  underactive bladder 
UPP  urethral perfusion pressure 
UPPbase  urethral perfusion pressure at the bladder filling phase 
UPPnadir the minimum urethral perfusion pressure at the urine voiding 
phase 
VE  voiding efficiency 
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General introduction 
While few people pay attention to maintaining continence and urinating at the 
appropriate time and in a controlled manner, these functions are fundamental for 
leading a normal daily life. The storage and periodic elimination of urine are 
coordinated between the bladder and a bladder outlet component such as the 
prostate or urethra. The reciprocal functional relationship between these 
components is controlled by a complex neural system (de Groat et al., 2015). During 
bladder filling, the sympathetic pathway releases noradrenaline and activates 1-
adrenoceptors to contract the proximal part of the urethra. Noradrenaline also 
activates 3-adrenoceptors expressed in the bladder to relax the detrusor smooth 
muscle for proper reservoir function of the bladder. When voiding urine, the 
parasympathetic pathway is activated to contract the bladder and relax the urethra 
by releasing acetylcholine and nitric oxide (NO), respectively, and adrenergic 
excitatory inputs are removed (Fowler et al., 2008).  
The continuing increase in average life expectancy and aging population in 
a growing number of countries is being accompanied by an increasing number of 
patients with urological disorders that affect their quality of life. Benign prostatic 
hyperplasia (BPH) is one of the most common chronic urological diseases among 
elderly men, with histological BPH being detected in 60% to 70% of men over 70 
years of age (Berry et al., 1984). Although the exact pathogenesis of histological 
BPH remains poorly understood, its clinical pathology is characterized by a 
hypertrophic nodule comprised of proliferative prostate epithelial cells and 
stromal cells around the prostatic part of the urethra (benign prostatic 
enlargement; BPE), mechanical and functional constriction of the prostate and 
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urethra causing bladder outlet obstruction (BOO), and lower urinary tract 
symptoms (LUTS). LUTS can be divided into two subgroups, voiding symptoms 
(problems in voiding urine) such as slow stream, straining, hesitancy, and terminal 
dribbling, and storage symptoms (problems in storing urine) such as urgency, 
daytime urinary frequency, and nocturia (Roehrborn, 2008). Although the 
traditional concept of BPH included all three of these elements, in many cases 
LUTS is not always correlated with clear evidence of BPE or BOO. Research 
suggests that functional abnormality of the prostate and urethra due to excess 
sympathetic inputs (McVary et al., 2005) and/or impaired nitrergic inputs (Klotz et 
al., 1999) may be involved in the voiding symptoms of LUTS. Meanwhile, 
dysregulation of bladder function is thought to contribute to storage symptoms 
(Chapple and Roehrborn, 2006), in addition to a decrease in functional bladder 
capacity due to post-void residual (PVR) urine resulting from BOO. 
Since it is generally assumed that the clinical manifestations of BPH are the 
result of BOO, pharmacological treatment strategy has been directed toward 
reducing BOO (McNicholas, 2012). α1-adrenoceptor antagonists (α1-blockers) are 
prescribed as the first-line pharmacotherapy for LUTS associated with BPH 
(LUTS/BPH). α1-blockers improve BOO by suppressing prostate and urethral 
smooth muscle contractions induced by norepinephrine released from sympathetic 
nerves (McNicholas, 2012). However, α1-blockers only moderately improve 
clinical symptoms (40% to 60%) compared to surgical intervention (60% to 80%) 
(Speakman, 2001), suggesting that further reduction of the obstruction can lead to 
further improvements in symptoms. In addition, the efficacy of α1-blockers on 
storage symptoms, which are sometimes considered more bothersome than 
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voiding symptoms (Chapple et al., 2014), is not always satisfactory (van 
Kerrebroeck et al., 2013). Furthermore, α1-blockers have little effect on prostate 
hyperplasia itself (Roehrborn, 2006), indicating its ineffectiveness for treating a 
fundamental component of BPH. Steroid 5α-reductase inhibitors, another class of 
pharmacotherapies, reduce the size of the enlarged prostate and improve 
symptoms caused by mechanical obstruction. However, 5α-reductase inhibitors 
have a slower onset of efficacy and are slightly less effective at improving LUTS 
than α1-blockers (Djavan, 2003). In addition, 5α-reductase inhibitors have little 
effect on stromal cell hyperplasia(Marks et al., 1997), a key component of human 
BPH (Bartsch et al., 1979). The type 5 phosphodiesterase (PDE5) inhibitor 
tadalafil has recently become clinically available for the treatment of LUTS 
associated with BPH, and has demonstrated additional potential benefits such as 
improving blood flow, anti-inflammatory effects, and afferent inhibitory effects 
(Andersson et al., 2011) . However, their positions in the treatment algorithm has 
not been fully established. Therefore, the unmet needs of current 
pharmacotherapies for BPH are as follows: i) potent relaxation of the bladder 
outlet component (prostate and urethra), ii) further improvement in storage 
symptoms, and iii) suppression of stromal cell proliferation. An agent that induces 
more potent urethral relaxation during voiding, suppresses stromal hyperplasia, 
and/or further improves bladder dysfunction is expected to improve treatment for 
LUTS/BPH patients. 
Lysophosphatidic acid (LPA) is a simple glycerophospholipid produced in 
various parts of the body with diverse biological actions, including smooth muscle 
contraction, cell proliferation, and afferent nerve stimulation (Aikawa et al., 2015; 
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Yung et al., 2015). In the lower urinary tract, LPA and autotaxin, an LPA 
synthesizing enzyme, are present in the seminal plasma (Tanaka et al., 2004). 
Acylglycerol kinase, another LPA synthesizing enzyme, is overexpressed in the 
hyperplastic prostate nodule (Zeng et al., 2009). LPA reportedly induces urethral 
smooth muscle contraction (Saga et al., 2014) and cell proliferation, such as that 
of prostatic smooth muscle cells isolated from BPH patients (Adolfsson et al., 
2002). In the bladder, LPA induces contraction of isolated detrusor smooth muscle 
cells (Kropp et al., 1999). These known functions of LPA suggest that it may play 
a physiological and pathophysiological role in mechanical (hyperplasia) and 
functional (contraction) BOO as well as bladder dysfunction (storage symptoms) 
observed in BPH. Therefore, suppressing LPA may contribute to improving 
LUTS/BPH, although its exact role in the lower urinary tract and its receptor 
subtype have not been fully elucidated.  
The effects of LPA are mediated by at least six G protein-coupled receptors, 
LPA receptors 1 to 6 (LPA1-6). Although these LPA receptors are broadly 
expressed, they vary significantly in their tissue distribution, and appear to have 
both distinct and overlapping biological roles (Choi et al., 2010). The type 1 LPA 
receptor (LPA1) was the first identified LPA receptor subtype. LPA1 couples with 
Gi/o, Gq/11, and G12/13 to initiate downstream signaling cascades through 
phospholipase C, mitogen-activated protein kinase (MAPK), Akt, and RhoA. 
LPA1 activation induces a range of cellular responses, including cell proliferation, 
cell migration and cytoskeletal changes, Ca2+ mobilization, and adenylyl cyclase 
inhibition (Yung et al., 2014). Prior studies using human samples have 
demonstrated more abundant expression of LPA1 than other LPA receptor 
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subtypes in the prostate with increased expression in the hyperplastic stroma 
compared to surrounding benign glands (Zeng et al., 2009) and in cultured bladder 
smooth muscle cells (Kawashima et al., 2015) with increased expression in 
muscle-invasive bladder cancer specimens (Kataoka et al., 2015). LPA1 mediates 
LPA-induced upregulation of CYR61 (Wu et al., 2014), which is overexpressed in 
BPH and is possibly linked to its progression (Sakamoto et al., 2004), suggesting 
that LPA1 may be associated with BPH. A recent study demonstrated that LPA1 
antagonists modulate urethral pressure (Terakado et al., 2016). In addition, a study 
suggested that LPA may be involved in stretch-induced cellular activation, 
possibly via LPA1 (Kawashima et al., 2015). These published findings suggest that 
LPA1 may have roles in the functional regulation of the lower urinary tract. 
However, the integrated functional role of LPA1 in the lower urinary tract has not 
been fully clarified. 
In this study, I investigated the functional role of LPA and LPA1 in the 
regulation of the lower urinary tract and the therapeutic potential of LPA1 
antagonism in the treatment of LUTS/BPH using ASP6432 (potassium 1-(2-{[3,5-
dimethoxy-4-methyl-N-(3-phenylpropyl)benzamido]methyl}-1,3-thiazole-4-
carbonyl)-3-ethyl-2,2-dioxo-2λ6-diazathian-1-ide; Figure 1-1), a novel LPA1 
antagonist discovered by Astellas Pharma Inc. In Chapter 1, the aim was to 
understand the function of LPA and LPA1 in the urethra and prostate by 
investigating the effects of LPA and ASP6432 on urethral and prostatic contractile 
function and prostate stromal cell proliferation. In Chapter 2, the role of LPA1 in 
the regulation of urethral tonus during urine voiding was pharmacologically 
examined by evaluating the effects of ASP6432 and tamsulosin, an 1-
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adrenoceptor antagonist, on urethral perfusion pressure (UPP) at the filling and 
voiding phases in anesthetized rats and on voiding dysfunction induced by Nω-
nitro-L-arginine methyl ester (L-NAME), an NO synthase inhibitor, in conscious 
rats. In Chapter 3, the effects of LPA and LPA1 on bladder functions were studied 
in conscious rats using continuous cystometry. In addition, the effect of ASP6432 
on urinary frequency induced by L-NAME was assessed in conscious rats. 
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Chapter 1: Effect of ASP6432, a Novel Type 1 Lysophosphatidic 
Acid Receptor Antagonist, on Urethral Function and Prostate Cell 
Proliferation 
 
Introduction 
BPH is one of the most common chronic urological diseases among elderly men. 
The proliferation of periurethral prostate stromal cells and contraction of prostate 
and urethral smooth muscles contribute to the development of BOO and LUTS 
(Roehrborn, 2008). Alpha1-blockers are prescribed as the first-line 
pharmacotherapy for LUTS associated with BPH (LUTS/BPH). Alpha1-blockers 
improve BOO by suppressing prostate and urethral smooth muscle contractions 
induced by norepinephrine released from sympathetic nerves. However, 
improvement of clinical symptoms with α1-blockers is moderate (40% to 60%) 
compared to surgical intervention (60% to 80%) (Speakman, 2001). In addition, 
α1-blockers are suggested to have little effect on prostate hyperplasia itself 
(Roehrborn, 2006). Steroid 5α-reductase inhibitors, another class of 
pharmacotherapies, reduce the size of the enlarged prostate and improve 
symptoms caused by mechanical obstruction. However, 5α-reductase inhibitors 
have a slower onset of efficacy and are slightly less effective at improving LUTS 
than α1-blockers (Djavan, 2003). In addition, 5α-reductase inhibitors have little 
effect on stromal cell hyperplasia (Marks et al., 1997), a key component of human 
BPH (Bartsch et al., 1979). Therefore, an agent that induces more potent urethral 
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relaxation and suppression of stromal hyperplasia would improve treatment for 
LUTS/BPH patients. 
LPA is a simple glycerophospholipid produced in various parts of the body. 
In the lower urinary tract, LPA and autotaxin, an LPA synthesizing enzyme, are 
present in the seminal plasma (Tanaka et al., 2004). In the hyperplastic prostate 
nodule, acylglycerol kinase, another LPA synthesizing enzyme, is overexpressed 
(Zeng et al., 2009). LPA has diverse biological effects including smooth muscle 
contraction (Tokumura et al., 1980), as shown by its induction of urethral smooth 
muscle contraction (Saga et al., 2014), and cell proliferation (Daaka, 2002), such as 
of prostatic smooth muscle cells isolated from BPH patients. These functions 
suggest that LPA may play a physiological and pathophysiological role in the 
mechanical and functional BOO observed in BPH.  
The functional roles of LPA are mediated by at least six G protein-coupled 
receptors (LPA1-6). Although these LPA receptors are broadly expressed, they vary 
significantly in their tissue distribution, and appear to have both distinct and 
overlapping biological roles(Choi et al., 2010). LPA receptors modulate various 
intracellular signaling pathways by activating multiple heterotrimeric G proteins. 
LPA1 was the first identified LPA receptor subtype. LPA1 couples with Gi/o, Gq/11, 
and G12/13 to initiate downstream signaling cascades through phospholipase C, 
mitogen-activated protein kinase, Akt, and RhoA. LPA1 activation induces a range 
of cellular responses, including cell proliferation, cell migration and cytoskeletal 
changes, Ca2+ mobilization, and adenylyl cyclase inhibition (Yung et al., 2014). An 
investigation using surgically-obtained human prostate tissue samples 
demonstrated LPA1 expression in both the stroma and epithelia, and increased 
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expression in the stroma of hyperplastic glands compared to that in surrounding 
benign glands (Zeng et al., 2009). LPA1 mediates LPA-induced induction of CYR61 
(Wu et al., 2014), a molecule overexpressed in BPH and possibly linked to its 
progression (Sakamoto et al., 2004), suggesting that LPA1 may be associated with 
BPH. A recent study demonstrated that LPA1 antagonists modulate urethral pressure 
(Terakado et al., 2016), suggesting that LPA1 may also have a role in urethral 
contraction. However, the integrated role of LPA1 in urethral and prostate function 
has not been fully clarified. 
ASP6432 (Figure 1-1) is a novel LPA1 antagonist discovered by Astellas 
Pharma Inc. To elucidate the function of LPA and LPA1 in the urethra and prostate, 
I investigated the effect of ASP6432 on urethral and prostatic contractile function 
and prostate stromal cell proliferation. 
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Materials and Methods 
Test substances 
LPA was purchased from Avanti Polar Lipids Inc. (Alabaster, AL, USA), Enzo 
Life Sciences International Inc. (Plymouth Meeting, PA, USA) and Cayman 
Chemical (Ann Arbor, MI, USA). Based on published literature (Saga et al., 
2014), 1-linolenoyl LPA was used for tissue contraction experiments, while 1-
oleoyl LPA, the most commonly used form of LPA(Castilla-Ortega et al., 2014), 
was used for all other studies. ASP6432 and tamsulosin were synthesized at 
Astellas Pharma Inc. (Tokyo, Japan). Concentrations were calculated using the 
molecular weight of the free form. 
 
Cells/recombinant expression 
Cells expressing LPA receptors were generated according to a previously reported 
method (Murai et al., 2017). Human and rat LPA1, human LPA2, and human LPA5 
were stably expressed in Chinese hamster ovary (CHO) cells and cultured in 
Minimum Essential Medium-alpha containing 10% heat-inactivated fetal bovine 
serum (FBS), 1% penicillin/streptomycin, and 100 nmol/L methotrexate. Human 
LPA3 was stably expressed in hepatoma tissue culture-4 (HTC4) cells and cultured 
in Dulbecco's Modified Eagle Medium (DMEM) containing 10% heat-inactivated 
FBS, 1% penicillin/streptomycin, and 70 μmol/L ZeocinTM. Human LPA4 was 
stably expressed in human embryonic kidney (HEK) cells and cultured in DMEM 
containing 10% FBS and 0.4 mg/mL G418.  
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Measurement of intracellular Ca2+ concentration 
The antagonistic effect of ASP6432 on human and rat LPA1 and its selectivity for 
human LPA1 over human LPA2 to human LPA4 were evaluated using Ca2+ flux 
assays previously used to investigate another LPA1 antagonist (Swaney et al., 2010), 
with some modifications. Briefly, cells were seeded at a density of 15,000 (LPA1 
and LPA2) or 20,000 (LPA3) cells per well in 96-well plates and incubated in culture 
medium containing 1% FBS for one day. HEK 293 cells expressing human LPA4 
were seeded at a density of 15,000 cells per well in 384-well plates and incubated 
in culture medium for one day.  
On the day the measurements were to be taken, the cells were loaded with 
Fluo-4-AM dissolved in assay buffer [Hank’s Balanced Salt Solution containing 
20 mmol/L 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (pH 7.4), 0.05% 
bovine serum albumin (BSA), and 2.5 mmol/L probenecid] for LPA1 to LPA3 or 
using the Fluo-4 NW Calcium Assay Kit (Invitrogen, Carlsbad, CA, USA) for LPA4, 
and incubated for 3 hours at room temperature (LPA1, LPA2, and LPA3) or 
30 minutes at 37°C (LPA4). The cells were incubated with test compounds for 2 
(LPA1) or 4 (LPA2 and LPA3) minutes after washing or 30 (LPA4) minutes without 
washing, and LPA at a final concentration of 100 (LPA1), 30 (LPA2) or 
800 (LPA3) nmol/L was added. The final concentration of LPA was determined for 
each cell line to produce a submaximal reaction. After LPA treatment, the change 
in fluorescence (excitation wavelength: 470-495 nm, emission wavelength: 515-
575 nm) was monitored using the fluorometric imaging plate reader FLIPR 
TETRA® (Molecular Devices Corporation Japan, Tokyo, Japan). For LPA4, 
2.8 µmol/L of LPA was used, and the change in fluorescence was measured using 
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the fluorometric imaging plate reader FLEX STATION-III (Molecular Devices, CA, 
USA) at an excitation wavelength of 494 nm and emission wavelength of 516 nm. 
 
Measurement of intracellular cyclic AMP 
The effect of ASP6432 on LPA-induced cyclic AMP (cAMP) production in cells 
expressing human LPA5 was evaluated using a previously described method (Murai 
et al., 2017). Briefly, CHO cells expressing human LPA5 were seeded at a density 
of 15,000 cells per well and cultured in 96-well plates. On the day the measurements 
were to be taken, ASP6432 or vehicle (dimethylsulfoxide: DMSO) was added to 
the cells with 1.3 mmol/L 3-isobutyl-1-methylxanthine (IBMX) and incubated for 
6 minutes. LPA (final concentration: 1 μmol/L) was subsequently added and the 
cells were incubated for 20 minutes at room temperature. After incubation, 1.2% 
Triton X-100 solution was added to stop the reaction. The amount of cAMP in the 
cell lysate was determined by the homogenous time resolved fluorescence (HTRF) 
assay using a cAMP kit (cAMP femto 2 bulk kit, Cisbio, Codolet, France).  
 
Measurement of isolated smooth muscle contraction 
All animal experimental procedures were approved by the Institutional Animal Care 
and Use Committee of Astellas Pharma Inc.  
Male Wistar rats (Charles River Laboratories Japan Inc., Kanagawa, Japan) 
were sacrificed by exsanguination under pentobarbital anesthesia. The ventral lobes 
of the prostate were immediately removed and divided into four longitudinal strips 
approximately 5 mm in length and 2 mm in width. The urethra located next to the 
bladder neck was cut open in a circular orientation to form a rectangular strip 
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approximately 5 mm in length and 2 mm in width. The tissue strips were suspended 
in 10 mL organ baths at 37°C containing Krebs-Henseleit solution consisting of the 
following (mmol/L): NaCl, 118.4; KCl, 4.7; KH2PO4, 1.2; MgSO4, 1.2; CaCl2, 2.5; 
NaHCO3, 25.0; and glucose, 11.1. Each bath was gassed with a mixture of 95% O2 
and 5% CO2. After loading with 0.5 g of initial resting tension, the force was 
measured using an isometric force displacement transducer (TB-611T, Nihon 
Kohden, Tokyo, Japan), a pressure amplifier (AP-621G, Nihon Kohden) and a 
recorder (SR6211, SR6221 or SR6335; Graphtec Corporation, Kanagawa, Japan). 
Each tissue strip was repeatedly contracted with 60 mmol/L KCl until a stable 
response was obtained. Subsequently, 100 μmol/L LPA was applied and the 
maximum contractile response was recorded as the initial LPA response. The 
concentration of LPA was selected according to a previous study (Saga et al., 2014) 
and our preliminary study in which we aimed to generate the maximum contraction 
under experimentally feasible conditions. In our preliminary study, LPA-induced 
contraction was observed from 1 μmol/L but did not reach maximum even at 
100 μmol/L (Figure 1-2). However, at 300 μmol/L, the solution became cloudy, 
making it difficult to continue with the experiment (data not shown). We therefore 
selected 100 μmol/L LPA as the test concentration.  
After washing, the strip was incubated with ASP6432 (0.01 to 10 μmol/L for 
urethra, 0.001 to 10 μmol/L for prostate) or vehicle (DMSO, 0.1%) for 30 minutes 
before the addition of LPA (100 μmol/L). The LPA-induced contractile response 
following treatment with ASP6432 or vehicle was recorded and expressed as a 
percentage of the initial LPA response (pre-value). For urethral strips, multiple 
concentrations (0.01 to 10 μmol/L) of ASP6432 were tested in an incremental 
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manner on the same strip because repeated treatment with DMSO and LPA did not 
affect the amplitude of the contractile response (data not shown). In contrast, only 
one concentration of ASP6432 was tested on each prostate strip due to the 
attenuation of LPA-induced contractile responses after multiple treatments (data not 
shown). 
 
Measurement of intraurethral pressure (IUP) in rats 
Male Wistar rats (Charles River Laboratories Japan Inc.) were anesthetized with an 
intraperitoneal administration of urethane (1.2 g/kg). A midline incision was made 
in the abdominal wall, and a 3.5 F sensor-tip transducer catheter (SPR-524, Millar 
Instruments. Inc., Houston, TX, USA) was inserted into the urethra through a small 
incision at the superior aspect of the bladder. IUP was measured using a pressure 
amplifier (AP-601G, Nihon Kohden) and analyzed using a digital acquisition and 
analysis system (PowerLab 8/30, AD Instruments, Colorado Springs, CO, USA). 
For intravenous (iv) administration, a polyethylene catheter (PE-50) filled with 
physiological saline containing sodium heparin was inserted into the jugular vein. 
Following a stabilization period of at least 30 minutes, vehicle (physiological saline 
with 5% dimethylformamide) or ASP6432 (0.03, 0.1, 0.3, and 1 mg/kg with 
incremental dosing at 15-minute intervals) was intravenously injected through the 
catheter. LPA (3 mg/kg iv) was administered 5 minutes after vehicle or ASP6432 
administration. The dose of LPA that induced an IUP increase comparable to that 
induced by the α1-blocker phenylephrine (30 μg/kg iv) reported in another study 
(Akiyama et al., 1999) was used to evaluate the effect of ASP6432. The area under 
the curve (AUC) of IUP at one minute before vehicle injection was defined as the 
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pre-value. The change in IUP induced by LPA following either vehicle or ASP6432 
treatment was defined by the AUC at one minute after LPA injection. 
 
Measurement of urethral perfusion pressure (UPP) 
UPP was measured according to a previously described method(Kurihara et al., 
2016). Briefly, female Wistar rats (Charles River Laboratories Japan Inc.) were 
anesthetized with an intraperitoneal injection of urethane (1.2 g/kg) and fixed in the 
supine position. For drug administration, a polyethylene catheter (PE-50) was 
inserted into the left femoral vein. For measurement of UPP, a midline incision was 
made in the abdominal wall and a double-lumen polyethylene catheter (PE-190 and 
PE-50) was inserted through a small incision at the bladder apex, and the tip was 
ligated to the bladder neck. Female rats were used because it was easier and less 
invasive to fix the position of the tip of the catheter at the bladder neck compared 
to that in male rats as there is no need to remove the ventral lobe of the prostate. 
Physiological saline was perfused into the urethra through the outer lumen of the 
catheter using an infusion pump (TE-331, Terumo, Tokyo, Japan) at 4.5 mL/h. UPP 
was recorded through the inner lumen of the catheter, which was connected to a 
pressure transducer with an amplifier (AP-601G or AP-621G, Nihon Kohden) and 
recorder (WT-688G, Nihon Kohden).  
After a stabilization period of over 30 minutes, rats with a UPP lower than 
10 mmHg were excluded from further evaluation. Vehicle (physiological saline for 
tamsulosin, physiological saline with 5% dimethylformamide for ASP6432), 
tamsulosin (0.003, 0.01, and 0.03 mg/kg) or ASP6432 (0.1, 0.3, 1 and 3 mg/kg) was 
administered intravenously, and the change in UPP was measured for 15 minutes. 
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The change between UPP before administration (UPPpre) and the minimum UPP 
during the observation period (UPPmin) was calculated as follows: 
UPP (% change from pre): -100×(UPPpre - UPPmin)/UPPpre 
 
Cell proliferation assay 
Primary cultured normal human prostate stroma cells (Lonza Walkersville Inc., 
Walkersville, MD, USA) were cultured in Stromal Cell Growth Medium (SCGM; 
Lonza Walkersville Inc.). Cells were suspended in SCGM diluted 10 times with 
stromal cell basal medium (Lonza Walkersville Inc.) containing 0.1% BSA, seeded 
at a density of 5,000 cells per well in 96-well plates and incubated overnight. 
ASP6432 (final concentration: 0.1 to 10 μmol/L) and LPA (final concentration: 
10 μmol/L) were added the next day and incubated for 24 hours. The final 
concentration of LPA was selected according to a previous study (Adolfsson et al., 
2002). Incorporation of bromodeoxyuridine (BrdU) into cells was measured using 
an ELISA kit (Cell Proliferation ELISA, BrdU (colorimetric), Roche Diagnostics 
GmbH, Mannheim, Germany). Optical densities at 450 nm and 690 nm were 
measured using a spectrophotometer (Spectramax M2, Molecular Devices Japan 
KK, Tokyo, Japan) and the difference in values at these wavelengths was used to 
indicate the extent of BrdU incorporation. The result was expressed as a percentage 
of the normal (LPA non-treated, DMSO-treated) group.  
 
Data analysis 
The results are presented as mean ± standard error of the mean (SEM). Half 
maximal inhibitory concentration (IC50) values were calculated using sigmoid-
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Emax non-linear regression analysis and expressed as the geometric mean with 
95% confidence interval for LPA1. In the tissue contraction study, Williams’ 
multiple comparisons test was used, and a probability value (p value) less than 
0.025 indicated statistical significance. In the in vivo studies, Dunnett’s multiple 
comparisons test and Student’s t-test were used, and p<0.05 was considered 
statistically significant. In the cell proliferation assay, paired t-test and Williams’ 
multiple comparisons test were used, and p<0.05 and p<0.025 were considered 
statistically significant, respectively.  
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Results 
Antagonistic effect of ASP6432 on the LPA1 receptor and its receptor subtype 
selectivity 
The potency of ASP6432 for LPA1 and selectivity for the different LPA receptors 
was determined by Ca2+ flux assays (for LPA1 to LPA4) and a cAMP assay (for 
LPA5) using cells over-expressing human LPA1 to LPA5. ASP6432 concentration-
dependently inhibited the LPA-stimulated increase in intracellular calcium ion 
concentration ([Ca2+]i) in cells expressing human LPA1 with an IC50 (95% 
confidence interval) value of 11 (6.8 to 18) nmol/L. ASP6432 also inhibited the 
LPA-induced [Ca2+]i increase in cells expressing rat LPA1 with an IC50 of 30 (19 to 
45) nmol/L. ASP6432 inhibited the LPA-induced [Ca2+]i increase in cells 
expressing human LPA4 with an IC50 of 114 nmol/L. In contrast, ASP6432 at 
concentrations up to 10,000 nmol/L did not inhibit the LPA-induced increase in 
[Ca2+]i by 50% or more in cells expressing human LPA2 or LPA3. Likewise, 
ASP6432 at concentrations up to 30,000 nmol/L did not affect the LPA-induced 
increase in cAMP in cells expressing human LPA5. These results are summarized 
in Table 1-1. 
The affinity of ASP6432 for a total of 57 receptors, ion-channels, transporters, 
and enzymes were also evaluated. ASP6432 at 10,000 nmol/L did not exhibit 
significant (>50%) effects on any of the targets examined, except for the human 
neurokinin 1 receptor with a Ki value of 1400 nmol/L (data not shown). 
 
Inhibition of LPA-induced contractions of urethral and prostate strips isolated 
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from rats by ASP6432 
Application of LPA (0.1 to 100 µmol/L) induced contractions in urethral and 
prostate tissue strips (N=5-7) (Figure 1-2). Pretreatment with ASP6432 (0.001 or 
0.01 to 10 µmol/L) inhibited these LPA (100 µmol/L)-induced contractions in both 
tissues in a concentration-dependent manner (N=5). This effect was statistically 
significant at ASP6432 concentrations of 0.1 µmol/L and above, with almost 
complete inhibition observed at 10 μmol/L (Figure 1-3).  
 
Inhibition of LPA-induced IUP elevation in anesthetized rats by ASP6432 
Intravenous administration of LPA (3 mg/kg iv) increased the IUP (Figure 1-3) by 
759 mmHg·min (17.2 cmH2O·sec). This was comparable to the effects of 
phenylephrine shown in a previous study (approximately 12 cmH2O at 30 μg/kg iv 
in rats with no urethral ligation) (Akiyama et al., 1999). ASP6432 (0.03 to 1 mg/kg 
iv) dose-dependently inhibited the LPA-induced IUP elevation (N=6). This effect 
was statistically significant at ASP6432 doses of 0.3 mg/kg and above, with almost 
complete inhibition observed at 1 mg/kg (Figure 1-4). The mean plasma 
concentration of ASP6432 in rats at 6 and 30 minutes after single intravenous 
administration at 1 mg/kg was 477.28 and 77.65 ng/mL (851.24 and 138.49 nmol/L, 
calculated from the free form molecular weight of 560.69), respectively (N=3) 
(Table 1-2).  
 
Decrease in UPP by tamsulosin and ASP6432 in anesthetized rats 
Intravenous administration of tamsulosin (0.003 to 0.03 mg/kg) decreased the UPP 
(N=7 to 15). This effect was statistically significant at a dose of 0.01 mg/kg iv, 
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maximally decreasing the UPP by 21.6% from baseline (Figure 1-5A). Intravenous 
administration of ASP6432 (0.1 to 3 mg/kg) decreased the UPP in a dose-dependent 
manner (N=10). This effect was statistically significant at ASP6432 doses of 
0.3 mg/kg iv and above. The decrease in UPP with ASP6432 reached a maximum 
of 42.5% at 3 mg/kg iv (Figure 1-5B). 
 
Effect of ASP6432 on LPA-induced proliferation of primary cultured human 
prostate stromal cells 
LPA (10 μmol/L) significantly enhanced the incorporation of BrdU into human 
prostate stromal cells (172.7% of the normal group). Treatment with ASP6432 (0.1 
to 10 µmol/L) suppressed LPA-induced BrdU incorporation in a concentration-
dependent manner. This effect was statistically significant at ASP6432 
concentrations of 0.3 μmol/L and above, with almost complete suppression 
observed at 10 μmol/L (Figure 1-6). 
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Discussion 
In this chapter, I showed that ASP6432 had potent and selective antagonistic 
activity against LPA1, and suppressed not only LPA-induced urethral and prostatic 
contractions but also urethral pressure in the absence of external LPA stimulation. 
These results suggest that LPA1 activation plays an important role in the 
physiological regulation of urethral tonus. In addition, ASP6432 inhibited the LPA-
induced proliferation of human prostate stromal cells. To my knowledge, this is the 
first study to demonstrate that an LPA1 antagonist can modulate both LPA-induced 
urethral tonus and prostate stromal cell proliferation.  
In the in vitro studies, ASP6432 exhibited a potent antagonistic effect against 
LPA1, and was more selective for LPA1 by more than ten-fold over all other LPA 
receptor subtypes (Table 1-1) and other receptors, ion-channels, transporters, and 
enzymes tested. Although ASP6432 showed some antagonistic activity against 
LPA4 and its effect on LPA6 was not investigated, ASP6432 appears to be one of 
the most potent LPA1 antagonists among currently reported LPA receptor 
modulators (Llona-Minguez et al., 2015). 
LPA was previously reported to induce contractions in rat urethral tissue strips 
at a magnitude comparable to that of phenylephrine, an α1-adrenoceptor agonist 
(Saga et al., 2014). However, the receptor subtype responsible for this effect was 
not identified. I showed that LPA induced contractions in rat urethral and prostate 
strips (Figure 1-2) and ASP6432 concentration/dose-dependently inhibited LPA-
induced contractions (Figure 1-3) and IUP elevation in anesthetized rats (Figure 1-
4) with near-complete inhibition at the highest concentration/dose tested. These 
results indicate that LPA1 regulates LPA-induced urethra and prostate contractions. 
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One notable finding in this study was that ASP6432 not only inhibited LPA-
induced contractions, but also reduced the UPP in the absence of exogenous LPA 
stimulation in anesthetized rats (Figure 1-5B). ASP6432 maximally decreased the 
UPP by 42.5% from baseline, which is more pronounced than that induced by 
tamsulosin in this study (maximum 21.6% decrease, Figure 1-5A) at doses 
sufficient to inhibit phenylephrine-induced urethral pressure elevation (Ohtake et 
al., 2006). Female rats were used in our study because of the similar efficacy of 
tamslosin when compared to male rats, the experimental benefit, and the potentially 
limited advantage of male rats as a model for urethral tonus in humans from an 
anatomical point of view. The tamsulosin-induced suppression of the UPP was 
similar to that demonstrated in a previous study in male rats (around 20% decrease) 
(Saga et al., 2014). Tamsulosin decreased the urethral pressure in male and female 
dogs at a similar dose range(Ohtake et al., 2004; Sudoh et al., 1996), and in healthy 
women at a dose approved for men with BPH (0.4 mg) (Reitz et al., 2004). These 
findings support the notion that the sympathetic nervous system and α1-
adrenoceptors contribute to regulating physiological urethral tonus (Fry et al., 2010) 
in both males and females. Another reason for using female animals was the 
experimental benefit for evaluating the perfusion pressure. In female rats, access to 
the bladder neck and subsequent securing of the catheter tip at the intended position 
was much easier and less invasive than that in male rats, which helped ensure stable 
pressure measurements. Further, the use of male rats might not significantly 
increase the clinical relevance of the UPP compared with that of female rats, 
because the rat prostate is anatomically different from the human prostate in that it 
does not completely surround the urethra, and therefore may not cause the 
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mechanical and/or functional urethral obstruction like the prostate of a BPH patient 
does. These points indicate that the experimental conditions of this study were 
appropriate for examining the effect of a drug that potentially modulates the urethral 
contraction in vivo compared with a drug acting on the sympathetic nervous system. 
LPA induced contraction of urethral strips at 1 mol/L and above in a 
previous study (Saga et al., 2014) and in the present study (Figure 1-2). The fact 
that the rat plasma LPA concentration reported in the previous study was in the 
micromolar order (around 1 mol/L) (Saga et al., 2014) suggests that LPA induces 
urethral contraction at a concentration similar to the endogenous concentration. In 
addition, previous studies have demonstrated that an inhibitor of autotaxin and 
another LPA1 antagonist decrease the IUP in the absence of exogenous LPA 
stimulation in rats (Saga et al., 2014; Terakado et al., 2016) to a similar extent to 
that observed with ASP6432 in this study. Moreover, pharmacokinetics data of 
ASP6432 in rats (Table 1-2) support my hypothesis that ASP6432 reduces UPP by 
suppressing LPA1. The plasma concentration of ASP6432 at the efficacious dose 
for urethral pressure (0.3 mg/kg iv, Figure 1-5) is estimated to be around 40 to 
250 nmol/L, which is comparable to the IC50 value of ASP6432 on rat LPA1 
(30 nmol/L, Table 1-1). Taken together, the results of this study suggest that 
endogenous LPA constantly activates LPA1 and plays a significant role in the 
regulation of urethral tonus, which is suppressed by ASP6432, at least in rats. 
LPA induces proliferation of human prostate stromal cells, similar to that 
observed for cells isolated from BPH patients(Adolfsson et al., 2002). ASP6432 
suppressed this proliferation (Figure 1-6). These results suggest that LPA, in 
addition to its role in inducing urethral and prostate contractions, also regulates 
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stromal cell proliferation via LPA1 and contributes to the development of the two 
major components, mechanical and functional obstruction, of BOO. Because there 
is currently no pharmacotherapy that is simultaneously efficacious for both of these 
components, the present findings indicate that LPA1 antagonists may represent a 
novel therapy with dual mechanisms for improving BOO. A similar concept was 
proposed using inhibitors of Rac, a small monomeric GTPase (Wang et al., 2015). 
Given that LPA1 may also potentially activate Rac (Van Leeuwen et al., 2003), it 
would be interesting to determine the relationship between LPA1 and Rac in lower 
urinary tract functions. 
Since autotaxin is one of the primary enzymes responsible for LPA production, 
autotaxin inhibitors may theoretically have similar efficacy to LPA1 antagonists, 
such as in reducing the IUP as shown in a previous study(Saga et al., 2014). Various 
autotaxin inhibitors have been studied and some are in clinical development. While 
inhibition of LPA production may efficiently suppress the LPA-LPA receptor 
signaling axis, the risk of toxicity may be high due to the suppression of functions 
mediated by other LPA receptor subtypes. Indeed, autotaxin knockout mice show a 
more severe phenotype (lethal around embryonic day 10.5 due to defects in blood 
vessel formation) than LPA receptor knock-out mice(Tanaka et al., 2006). Therefore, 
specific targeting of LPA1 may be more suitable for the treatment of non-life-
threatening diseases like BPH, which require a high safety profile. 
The present study results provide various insights for further investigations 
into the role of LPA and LPA1. The physiological and pathophysiological role of the 
LPA-LPA1 signaling axis in the modulation of urethral pressure has not been 
extensively investigated. Currently, no study has directly measured the tissue 
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concentration of LPA in the urethra or prostate, even though the presence of LPA in 
seminal plasma (Tanaka et al., 2004)(Tanaka et al., 2004) and LPA-producing 
enzymes in the prostate (Zeng et al., 2009) suggest that it may be produced locally 
in these organs. The mechanism underlying LPA1 activation-induced urethral and 
prostate smooth muscle contractions has not been fully clarified. In mouse aorta, 
LPA1-mediated thromboxane A2 release has been suggested as a potential 
mechanism underlying smooth muscle contraction(Dancs et al., 2017). However, 
studies showing that an autotaxin inhibitor (Saga et al., 2014) and LPA1 antagonist 
(Terakado et al., 2016) decrease the urethral pressure without affecting blood 
pressure suggest the presence of an alternative mechanism for regulating urethral 
smooth muscle contraction. Further studies are required to unravel the mechanistic 
details. In addition, the role of LPA1 on urethral pressure during urine voiding needs 
to be determined. Since the sympathetic and parasympathetic nervous system 
regulate the on-off of the bladder and the urethral outlet functions in an antagonistic 
fashion for proper urine storage and voiding(Fowler et al., 2008), it would be 
worthwhile to investigate how the activity of LPA1 is regulated at bladder filling 
and urine voiding. The effect of LPA1 on bladder function represents another area 
of interest. While the effect on pathological prostate proliferation should ideally be 
assessed using in vivo models, fully validated animal models for stromal 
proliferation are currently lacking. Future studies on these aspects will allow for a 
more extensive characterization of the therapeutic potential of LPA1 antagonists in 
the treatment of BPH and associated LUTS.  
In conclusion, I demonstrated the roles of LPA and LPA1 in urethral and prostate 
contraction and prostate stromal cell proliferation using ASP6432, a selective 
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LPA1 antagonist. ASP6432 induced potent urethral relaxation compared to 
tamsulosin and inhibited prostate stromal cell growth, indicating the potential of 
an LPA1 antagonist as a novel therapy for LUTS/BPH. 
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Table 1-1. Antagonistic activity of ASP6432 on lysophosphatidic acid (LPA)-
induced cellular responses in cells expressing LPA1 to LPA5 receptors 
 LPA1 (Human) 
LPA1 
(Rat) 
LPA2 
(Human) 
LPA3 
(Human) 
LPA4 
(Human) 
LPA5 
(Human) 
IC50 
(nmol/L) 11 30 >10,000 >10,000 114 >30,000 
  
Effects of ASP6432 on the LPA-induced increase in intracellular Ca2+ (LPA1 to 
LPA4) or cyclic AMP (LPA5) were measured, and IC50 values were calculated using 
sigmoid-Emax non-linear regression analysis and expressed as the geometric mean 
of two to four independent experiments.  
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Table 1-2. Plasma concentrations of ASP6432 in rats after single intravenous 
(1 mg/kg) administration 
Time 
after 
dosing 
(h) 
Plasma concentration (ng/mL) 
0.1 0.25 0.5 1 2 4 
Mean 477.28 168.84 77.65 40.18 22.41 10.49 
SD 41.85 5.04 5.33 6.77 2.68 1.74 
 
Male F344/DuCrlCrlj rats (7 weeks) were used. ASP6432 was dissolved in a 
polyethylene glycol 400/water (1:1, v/v) solution and administered intravenously 
(1 mg/mL/kg). 
Plasma samples were collected, and plasma concentration was determined using 
liquid chromatography-tandem mass spectrometry. Results were expressed as the 
mean and standard deviation (SD) of three animals. 
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Figure 1-1. Chemical structure of ASP6432 (potassium 1-(2-{[3,5-dimethoxy-
4-methyl-N-(3-phenylpropyl)benzamido]methyl}-1,3-thiazole-4-carbonyl)-3-
ethyl-2,2-dioxo-2λ6-diazathian-1-ide) 
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 Figure 1-2. Contractile effects of lysophosphatidic acid (LPA) on isolated rat 
urethra (A) and prostate (B) tissue strips 
Tissue strips were treated with 0.1 to 100 μmol/L LPA to elicit contractile responses. 
Each point represents the mean ± SEM of seven (urethra) or five to six (prostate) 
strips. 
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Figure 1-3. Effect of ASP6432 on lysophosphatidic acid (LPA)-induced 
contractions in isolated rat urethra (A) and prostate (B) 
For the urethra (A), tissue strips were incubated with vehicle or various 
concentrations of ASP6432 for 30 minutes before 100 μmol/L LPA was added to 
elicit a contractile response. Each column represents the mean ± SEM of five strips. 
Pre: initial LPA-induced contraction response. *p<0.025 vs. pre (initial LPA 
contraction) (Williams’ multiple comparisons test using within-subject error). 
For the prostate (B), tissue strips were incubated with ASP6432 or vehicle (DMSO) 
for 30 minutes before 100 μmol/L LPA was added to elicit a contractile response. 
Each column represents the mean ± SEM of five strips. *p<0.025 vs. vehicle 
(Williams’ multiple comparisons test). 
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Figure 1-4. Effect of ASP6432 on lysophosphatidic acid (LPA)-induced 
intraurethral pressure (IUP) elevation in anesthetized rats  
IUP was measured in male Wistar rats under urethane anesthesia. LPA (3 mg/kg iv) 
was administered five minutes after treatment with vehicle or ASP6432 (0.03 to 
1 mg/kg iv), and the area under the curve (AUC) of IUP was recorded for one 
minute. The AUC at one minute before vehicle injection is represented as Pre-value. 
Each column represents the mean ± SEM of six animals. 
**p<0.01 vs. vehicle (Dunnett’s multiple comparisons test).  
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Figure 1-5. Effect of tamsulosin (A) and ASP6432 (B) on the urethral 
perfusion pressure (UPP) in anesthetized rats 
UPP was measured in female Wistar rats under urethane anesthesia. Vehicle, 
tamsulosin (0.003 to 0.03 mg/kg iv) or ASP6432 (0.1 to 3 mg/kg iv) was 
administered, and the UPP was recorded for 15 minutes. The maximum change in 
UPP from baseline (%) was calculated for each animal. Each column represents the 
mean ± SEM of 7 to 15 animals.  
Veh: vehicle, Tam: tamsulosin (0.01 mg/kg iv). ##p<0.01 vs. vehicle (Student’s t-
test); *p<0.05, **p<0.01 vs. vehicle (Dunnett’s multiple comparisons test). 
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Figure 1-6. Effect of ASP6432 on lysophosphatidic acid (LPA)-induced 
bromodeoxyuridine incorporation into primary cultured human prostate 
stromal cells 
The incorporation of bromodeoxyuridine (BrdU) into cells was measured in 
primary cultured normal human prostate stromal cells. The extent of BrdU 
incorporation was expressed as a percentage of that of the normal group (non LPA-
treated). Each experiment was conducted in triplicate and each column represents 
the mean ± SEM of four experiments.  
N: normal (non LPA-treated), C: control (treated with LPA and vehicle). #p<0.05 
vs. normal (paired t-test), *p<0.025 vs. control (William’s multiple comparisons 
test using within-subject error). 
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Chapter 2: Effect of ASP6432 on Urethral Function during Urine 
Voiding and Voiding Dysfunction 
 
Introduction 
The storage and periodic elimination of urine require coordination between the 
bladder and a bladder outlet component such as the urethra. The neural pathways 
controlling this coordination are organized as simple on-off circuits to maintain a 
reciprocal relationship. Throughout bladder filling, the sympathetic pathway 
releases noradrenaline, activates 1-adrenoceptors, and contracts the proximal 
urethra. At the urine voiding phase, the parasympathetic pathway is activated to 
contract the bladder, and the urethra is relaxed by the release of nitric oxide (NO) 
and removal of adrenergic excitatory inputs (Fowler et al., 2008).  
Functional dysregulation between the bladder and urethra causes voiding 
dysfunctions. Increased urethral tonus during voiding due to excessive sympathetic 
inputs (McVary et al., 2005) or impaired nitrergic inputs (Klotz et al., 1999) leads 
to incomplete bladder emptying and LUTS. Although pharmacotherapies for 
reducing urethral tonus such as 1-adrenoceptor antagonists (1 blockers) are 
available for LUTS with BPH, their efficacy for other types of voiding dysfunctions 
such as female LUTS has not been established (Bae et al., 2005). Therefore, an 
agent that potently relaxes the urethra could improve treatment for voiding 
dysfunction and LUTS associated with BPH or other urology diseases.  
LPA is a small ubiquitous glycerophospholipid found in vertebrate organisms 
that mediates diverse biological actions (Yung et al., 2014). The functional roles of 
LPA are primarily mediated by at least six G protein-coupled receptors, LPA1–6. 
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Although these LPA receptors are broadly expressed, they vary significantly in their 
tissue distribution and appear to have both distinct and overlapping biological roles 
(Choi et al., 2010). LPA1 was the first identified LPA receptor subtype. LPA1 is 
broadly expressed in various tissues, including the normal and hyperplasic prostate 
(Zeng et al., 2009). LPA1 activation induces a range of biological responses such as 
smooth muscle contraction and cell proliferation. Recent studies using 
pharmacological tools demonstrate that LPA and LPA1 are involved in contraction 
of the urethra in rats (Saga et al., 2014; Terakado et al., 2016). 
In Chapter 1, I demonstrated that ASP6432, a novel compound discovered by 
our group, demonstrated potent antagonistic activity against LPA1 
(IC50=11 nmol/L) and was more than 10-fold selective for LPA1 over other LPA 
receptor subtypes and other receptors, ion channels, transporters, and enzymes 
tested. ASP6432 suppressed not only LPA-induced urethral and prostatic 
contractions but also urethral perfusion pressure (UPP) in the absence of external 
LPA stimulation in rats, as shown in Chapter 1. However, whether and to what 
extent an LPA1 antagonist can decrease the UPP at the voiding phase and improve 
voiding dysfunction has not been examined. 
In this chapter, to elucidate the role of LPA1 in the regulation of urethral tonus 
during urine voiding, I investigated the effects of ASP6432 and tamsulosin, an 1 
blocker, on UPP at the filling and voiding phases in anesthetized rats. In addition, 
the effects of ASP6432 and tamsulosin on voiding dysfunction induced by Nω-nitro-
L-arginine methyl ester (L-NAME), an NO synthase inhibitor, was evaluated in 
conscious rats. 
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Materials and Methods 
Test reagents 
ASP6432 (Figure 1-1) and tamsulosin were synthesized at Astellas Pharma Inc. 
(Tokyo, Japan). For the study in anesthetized rats, ASP6432 and tamsulosin were 
dissolved and diluted in saline with 5% (v/v) dimethylformamide. For the 
experiment in conscious rats, tamsulosin was dissolved in distilled water and 
diluted with saline, and ASP6432 was dissolved and diluted in saline with 20% 
N,N-dimethylacetamide and 10% (v/v) Cremophor EL. The amount of these 
organic solvents and detergents used in this study was either below the clinical 
concentration, comparable to that used in a previous study, or much lower than the 
toxic exposure level. Nω-nitro-L-arginine methyl ester hydrochloride (L-NAME 
hydrochloride) (Sigma-Aldrich, St. Louis, MO, USA) was dissolved and diluted 
in saline. 
 
Experimental animals 
In total, 32 male and 40 female animals were used. Female Wistar rats were 
purchased from Charles River Laboratories Japan Inc. (Kanagawa, Japan). Male 
Sprague-Dawley rats were purchased from Japan SLC Co. Ltd. (Shizuoka, Japan). 
The number of animals per group was determined based on the expected effect size 
and standard deviation estimated from preliminary experiments. For the effect of 
tamsulosin on the L-NAME-induced model, the above estimation was not feasible 
since preliminary experiment showed that tamsulosin had no effect. Therefore, I 
terminated the experiment when we observed the same trend as that in our 
preliminary experiment, to keep the number of animals minimum. All animal 
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experimental procedures including the number of animals were approved by the 
Institutional Animal Care and Use Committee of Astellas Pharma Inc. Furthermore, 
Astellas Pharma Inc. Tsukuba Research Center was awarded Accreditation Status 
by the AAALAC International. 
Recording of UPP in anesthetized rats under isovolumetric conditions  
UPP was measured according to a previously described method (Jung et al., 1999) 
with some modifications. Female Wistar rats were anesthetized with an 
intraperitoneal injection of urethane (1.0 g/kg) and fixed in the supine position. For 
drug administration, a polyethylene catheter (PE-50) was inserted into the left 
femoral vein. A midline incision was made in the abdominal wall, and a double-
lumen polyethylene catheter (PE-160 and PE-50) was inserted through a small 
incision at the bladder apex, and the tip was positioned at the bladder neck. Two 
other polyethylene catheters (PE-50) were inserted into the bladder to measure 
intravesical pressure (IVP) and drain saline. Saline was perfused into the bladder 
dome through a catheter using an infusion pump (STC-525 or TE-331, Terumo, 
Tokyo, Japan; KDS100, Muromachi Kikai Co. Ltd., Tokyo, Japan or Neuroscience 
Inc., Tokyo, Japan) at 4.5 mL/h to induce isovolumetric rhythmic bladder 
contractions. Saline was also perfused into the urethra through the outer lumen of 
the double lumen-catheter at 4.5 mL/h to measure UPP. IVP and UPP were 
measured using a pressure transducer (TP-400T, Nihon Kohden, Tokyo, Japan) 
connected to a pressure amplifier (AP-601G or AP-621G, Nihon Kohden).  
After a stabilization period, vehicle (1 mL/kg), tamsulosin (0.01 mg/kg), or 
ASP6432 (0.1, 0.3, and 1 mg/kg) was administered intravenously (iv). The dose of 
tamsulosin used in this study (0.01 mg/kg iv) induced a maximum decrease in UPP 
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in the previous chapter. After drug administration, UPP at the bladder filling phase 
(UPPbase), the minimum UPP at the urine voiding phase (UPPnadir), the duration of 
urethral relaxation, the duration of high frequency oscillations (HFOs) reflecting 
external urethral sphincter muscle contraction (Bennett et al., 1995) (Figure 1A) for 
15 min, and maximum changes from baseline were recorded as % change from 
baseline. 
 
Voiding dysfunction model induced by L-NAME in conscious rats 
Voiding dysfunction, characterized by an increase in post-void residual urine (PVR) 
and a decrease in voiding efficiency (VE), was induced in conscious rats by 
intravenous administration of L-NAME (10 mg/kg). The dose of L-NAME was 
determined according to the preliminary experiment (data not shown).  
Voiding parameters were measured according to the method descried by 
Kurihara et al. (Kurihara et al., 2016) in male Sprague-Dawley rats. Under 
isoflurane anesthesia, a PE-160 catheter was inserted into the bladder through an 
abdominal incision and a small incision at the center of the ventral side of the 
bladder. The other end of the catheter was exited through the abdominal incision in 
a vertical direction to infuse saline and collect residual urine. A PE-50 catheter was 
inserted into the jugular vein for drug administration. After surgery, the rat was 
placed in a Ballman cage (Natsume Seisakusho, Tokyo, Japan) and allowed to 
recover from anesthesia for at least 1 hour. The bladder catheter (PE-160) was 
connected to a pressure transducer (DX-100; Nihon Kohden) and an infusion pump 
(TE-331S, STC-525 or STC-528; Terumo) via a three-way stopcock. Intravesical 
pressure was monitored using an amplifier (AP-601G; Nihon Kohden) connected 
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to a pressure transducer.  
Voiding parameters were measured by running single cystometry (CMG) twice 
(Figure 3A). The first CMG was to collect baseline values. Saline was infused into 
the bladder at 4.2 mL/h. The infusion was stopped immediately after initiation of 
the voiding reflex, and urine voided from the urethral orifice and PVR were 
collected and weighed using an electronic balance (GX-200; A and D, Tokyo, 
Japan). After the first series of CMGs, vehicle (1 mL/kg iv), ASP6432 (0.3, 1 or 
3 mg/kg, iv), or tamsulosin (0.003 or 0.01 mg/kg iv) was administered. L-NAME 
was administered 5 min after drug administration. The second CMG was started 
5 min after L-NAME administration, and the voided urine and PVR were measured 
after voiding, and changes in PVR (mL) and VE (%) from the respective baseline 
values were calculated. A weight of 1 g of urine was considered to be equivalent to 
a volume of 1 mL of urine. Voiding efficiency (VE) was calculated using the 
following formula:  
VE (%)=100×(voided volume [mL])/(voided volume [mL]+PVR [mL])  
Data analysis 
PowerLab and LabChart (ADInstruments Japan, Aichi, Japan) were used to 
collect data. Statistical analyses were performed using SAS software (SAS 
Institute Japan, Tokyo, Japan) or Prism (GraphPad Software, San Diego, CA, 
USA). Results are presented as mean±SEM. Student's t-test, paired t-test, one-way 
analysis of variance (ANOVA), or ANOVA followed by Dunnett’s multiple 
comparisons test was used, and p<0.05 was considered statistically significant.  
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Results 
ASP6432 but not tamsulosin decreased UPP during voiding in anesthetized 
rats under isovolumetric conditions 
Under isovolumetric conditions, the bladder and urethra produced simultaneous and 
periodic contractions and relaxations (Figure 2-1A and 2-1B). There were no 
significant differences in baseline UPPbase, UPPnadir, duration of urethral relaxation, 
or duration of HFOs at the voiding phase between groups (Table 2-1).  
Intravenous administration of tamsulosin (0.01 mg/kg) significantly decreased 
the UPPbase compared to the vehicle-treated group, but did not significantly alter the 
UPPnadir (Figure 2-1C, Figure 2-2A and 2B). Intravenous administration of 
ASP6432 (0.1 to 1 mg/kg) dose-dependently and statistically significantly 
decreased the UPPbase and UPPnadir at 1 mg/kg iv and 0.3 mg/kg iv and above, 
respectively (Figure 2-1D, Figure 2-2A and 2B). Neither tamsulosin nor ASP6432 
significantly changed the duration of HFOs or urethral relaxation at the urine 
voiding phase (Figure 2-1C and 1D, Figure 2C and 2D).  
 
ASP6432 but not tamsulosin improved L-NAME-induced voiding dysfunction 
in conscious rats 
Mean baseline values for PVR and VE were 0.04 to 0.06 mL and 94.1% to 96.2%, 
respectively (Table 2-2). No significant differences were observed between groups. 
In vehicle-treated groups, intravenous administration of L-NAME (10 mg/kg) 
increased PVR by 0.27 to 0.31 mL and decreased VE by 21.7% to 22.7%, with no 
significant changes in the time to voiding or maximum IVP (Figure 2-3B).  
Treatment with tamsulosin (0.003 and 0.01 mg/kg iv) did not affect either the 
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increase in PVR or the decrease in VE induced by L-NAME (Figure 2-4A). On the 
other hand, ASP6432 significantly prevented the increase in PVR and decrease in 
VE elicited by L-NAME at 1 mg/kg iv and above compared to the vehicle-treated 
group (Figure 2-4B). Neither tamsulosin nor ASP6432 significantly changed the 
time to voiding or maximum IVP (data not shown). 
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Discussion 
In this chapter, I demonstrated that the LPA1 antagonist ASP6432 decreased 
UPPnadir, while tamsulosin had no effect. ASP6432 also suppressed the increase in 
PVR and decrease in VE induced by L-NAME, while tamsulosin likewise had no 
effect. Although recent reports (Terakado et al., 2016) and the results in Chapter 1 
have demonstrated a significant role for LPA1 in maintaining urethral contraction, 
it has remained unclear whether LPA1 antagonism decreases urethral pressure at the 
voiding phase and if it actually affects urine voiding. To my knowledge, this is the 
first study to show that an LPA1 antagonist decreases urethral tonus during urine 
voiding and improves voiding dysfunction. 
In anesthetized rats under isovolumetric conditions, both ASP6432 and 
tamsulosin reduced UPPbase (Figure 2-2A), as shown in Chapter 1. Interestingly, 
ASP6432 also decreased UPPnadir, which was not significantly affected by 
tamsulosin (Figure 2-2B). The decrease in UPPnadir by ASP6432 suggests that 
activated LPA1 contributes to the regulation of urethral tonus at the voiding phase, 
in contrast to the notion that the sympathetic nervous system is not active at the 
voiding phase (Fowler et al., 2008). The decrease in UPPbase but not UPPnadir by 
tamsulosin is also consistent with this notion and prior findings that 1 blockers 
decrease the baseline UPP (Conley et al., 2001) but not UPP at the voiding phase 
(Bae et al., 2005). ASP6432 demonstrated high selectivity in an off-target assay that 
included 1-adrenceptors (Chapter 1, data not shown). To my knowledge, no study 
has shown a direct relationship between LPA1 and 1-adrenceptors. Comparison of 
the present study results with the above-mentioned studies suggests that inhibition 
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of LPA1 activation decreases urethral tonus at the voiding phase via a mechanism 
that is not directly related to 1-adrenoceptor antagonism. However, detailed studies 
are needed to determine whether there is any crosstalk between the LPA-LPA1 
signaling axis and the adrenergic system. 
To examine the benefit of decreasing UPPnadir on voiding dysfunction, I 
investigated the effect of ASP6432 and tamsulosin in a L-NAME-induced voiding 
dysfunction model in conscious rats. I used this approach instead of the 
measurement of UPPnadir in anesthetized rats under isovolumetric conditions, 
because in the preliminary experiment L-NAME frequently eliminated reflex 
urethral relaxation, which was also observed using another NOS inhibitor (Bennett 
et al., 1995), making it difficult to evaluate the effect of drugs on impaired urethral 
relaxation induced by L-NAME. Single CMG showed that L-NAME increased 
PVR and decreased VE without significantly altering bladder parameters (Figure 2-
3B), consistent with a prior study demonstrating that L-NAME primarily inhibits 
urethral relaxation at the voiding phase and increases PVR (Persson et al., 1992). 
ASP6432 prevented the L-NAME-induced decrease in VE and increase in PVR 
(Figure 2-4B). Given that ASP6432 decreased the UPPnadir (Figure 2-2B), it is 
reasonable to assume that ASP6432 prevented voiding dysfunction by decreasing 
urethral tonus during urine voiding via LPA1 antagonism, thereby functionally 
counteracting the impaired urethral relaxation induced by L-NAME. However, 
whether ASP6432 and L-NAME act independently or if there is interplay between 
them remains to be clarified. To my knowledge, only one study has investigated the 
relationship between LPA and NO-related signaling in smooth muscle tissue (the 
lower esophageal sphincter of cats) (Lee et al., 2011). While ASP6432 had no effect 
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on the duration of urethral relaxation and HFOs (Figure 2-2C and 2-2D), the non-
selective phosphodiesterase inhibitor zaprinast and NO donors reportedly enhance 
the duration of urethral relaxation (Jung et al., 1999; Wibberley et al., 2002), 
suggesting that ASP6432 may modulate urethral functions differently to drugs that 
act on the nitrergic pathway. More research is needed to elucidate the relationship 
between the LPA1 and nitrergic pathways.  
Tamsulosin did not affect the L-NAME-induced voiding dysfunction (Figure 
2-4A), even though the 1 blocker prazosin was previously shown to potentiate the 
relaxation effect of NO released from nerve endings in isolated rabbit urethra strips 
(Seshita et al., 2000). The effect of 1-blockers on NO-mediated urethral relaxation 
may be limited, or differ across experimental settings or species. Tadalafil, the only 
approved PDE5 inhibitor for the treatment of LUTS associated with BPH (Gacci et 
al., 2016), may suppress the effects of L-NAME. However, the effect of tadalafil 
was not evaluated in this study, because the L-NAME-induced model is not 
appropriate to compare the efficacy of the drug acting on the nitrergic pathway with 
those mainly acting on other pathways. In addition, PDE5 inhibitors enhance 
relaxation of the bladder (Filippi et al., 2007; Oger et al., 2010; Ribeiro et al., 2014) 
and tadalafil did not significantly improve maximum urine flow or PVR in the 
majority of clinical studies (Hatzimouratidis, 2014), suggesting that PDE5 
inhibition may not be an ideal approach for improving uroflowmetric parameters 
such as PVR and VE. 
The present study results provide various insights for further investigation into 
the role of LPA and LPA1. Given that this study suggests that the effect of ASP6432 
on urethral tonus is not directly related to 1-adrenoceptor antagonism, I expect that 
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ASP6432 will at least have an additive effect when combined with tamsulosin. 
However, further investigations into potential interactions between LPA1 and the 
adrenergic and nitrergic pathways are required to clarify the potential clinical 
benefit of the combined use of ASP6432 and 1 blockers or PDE5 inhibitors, as 
well as the physiological role of LPA1 in the lower urinary tract. The effects of LPA 
and LPA1 in the regulation of bladder function should also be investigated to 
elucidate their overall roles in the lower urinary tract. When studying the effect of 
LPA on bladder functions, it should be noted that LPA binds and directly activates 
molecular targets other than LPA receptors such as transient receptor potential 
(TRP) channel TRPV1 (Nieto-Posadas et al., 2011), TRPA1 (Kittaka et al., 2017), 
and peroxisome proliferator-activated receptor  (PPAR) (McIntyre et al., 2003), 
since TRPV1 and TRPA1 play important roles as sensors of stretch or chemical 
irritation to activate bladder sensory signaling (Skryma et al., 2011). However, for 
urethral functions, it is unlikely that these molecules are responsible for LPA-
induced urethral smooth muscle contractions, because other LPA1 antagonists have 
been shown to inhibit LPA-induced contractions (Terakado et al., 2017; Terakado 
et al., 2016) and TRPA1 agonists inhibit the contraction of isolated human urethral 
strips in cooperation with TRPV1-mediated signals (Weinhold et al., 2010). Further, 
it is unlikely that relatively rapid biological responses like smooth muscle 
contraction can be explained by transactivation of nuclear receptors like PPAR. 
The finding that ASP6432 significantly reduced the UPPnadir and suppressed L-
NAME-induced voiding dysfunction, while tamsulosin did not, suggests that 
ASP6432 has the potential to improve voiding dysfunctions that are refractory to 
current pharmacotherapies in humans. Hypofunction of NO mechanisms and 
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urethral dysfunction in aged rats (Kimura et al., 2018), impaired NO synthesis with 
increasing age in humans (Schulze et al., 2005; Yoshida et al., 2003), and voiding 
dysfunction in mice deficient of neuronal NO synthase (Burnett et al., 1997) suggest 
that patients with age-related urethral dysfunction may benefit from treatment 
withASP6432. Underactive bladder (UAB), a recently proposed disease entity 
(Chapple et al., 2018), may be another potential target indication given that 
treatments that solely target the bladder have been reported to be ineffective 
(Barendrecht et al., 2007), suggesting the need for alternative approaches (Deruyver 
et al., 2018). ASP6432 may be effective for improving bladder emptying by 
potently relaxing the urethra during voiding and correcting the relative imbalance 
between bladder contraction and urethral relaxation. 
Before investigating the therapeutic potential for ASP6432 in a clinical setting, 
extensive nonclinical profiling for pharmacokinetics and safety must be completed. 
Although the detailed data were not shown here, pharmacokinetic studies in rats 
and dogs demonstrated that the absolute bioavailability of ASP6432 ranged from 
34.7% to 76.7%, and that oral administration of ASP6432 showed no effect on 
blood pressure, heart rate, or electrocardiogram findings in dogs at up to 100 mg/kg. 
Although it was not feasible to evaluate the effect of ASP6432 on urethral functions 
after oral administration due to technical limitations, comparison of these results 
with the effective dose after intravenous administration (0.3 to 1 mg/kg; Figure 2-2 
and Figure 2-4) suggests that ASP6432 will have favorable oral absorption with 
expected efficacy after oral administration, and a low risk of cardiovascular side 
effects. Regarding toxicity, theoretical side effects assumed from findings in LPA1-
deficient mice, such as abnormalities in fetal development (Contos et al., 2000), 
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should be carefully assessed. However, the clinical study results of LPA1 
antagonists (Allanore et al., 2018; Palmer et al., 2018) suggest a low risk of 
mechanism-based serious toxicity precluding clinical application. Future studies on 
these aspects will provide a more extensive characterization of the therapeutic 
potential of ASP6432 in the treatment of voiding dysfunction. 
In conclusion, I demonstrated that ASP6432 but not tamsulosin decreased 
urethral pressure during urine voiding and improved L-NAME-induced voiding 
dysfunction. The results in this chapter suggest that LPA1 has a significant role in 
regulating urethral tonus during urine voiding, and highlight the potential of 
ASP6432 for improving voiding dysfunctions and LUTS associated with BPH and 
other lower urinary tract diseases. 
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Table 2-1. Baseline urethral perfusion pressure (UPP) parameters under 
isovolumetric conditions. 
Parameter Vehicle 
ASP6432 
(mg/kg iv) 
Tamsulosin 
(mg/kg iv) 
0.1 0.3 1 0.01 
UPPbase 
(mmHg) 
23.23 
±2.31 
24.57 
±2.59 
27.40 
±2.45 
26.13 
±2.06 
23.23 
±2.31 
UPPnadir 
(mmHg) 
9.51 
±0.97 
10.36 
±1.75 
10.22 
±1.19 
8.88 
±0.96 
9.09 
±1.09 
Urethral 
relaxation (s) 
26.5 
±4.9 
35.6 
±4.2 
36.9 
±2.3 
29.3 
±5.7 
31.4 
±5.3 
HFOs(s) 13.8 
±2.1 
14.7 
±2.0 
13.2 
±1.7 
15.6 
±3.2 
14.9 
±1.7 
 
UPPbase, baseline UPP at the bladder filling phase; UPPnadir, minimum UPP at the 
urine voiding phase; HFOs, high frequency oscillations. Values indicate the 
mean±SEM of eight animals. There were no statistical differences in any 
parameters between groups (one-way ANOVA). 
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Table 2-2. Baseline cystometric parameters of each treatment group. 
Parameter ASP6432 (mg/kg iv) Tamsulosin (mg/kg iv) Veh. 0.3 1 3 Veh. 0.003 0.01 
PVR 
(mL) 
0.05 
±0.02 
0.06 
±0.01 
0.04 
±0.01 
0.06 
±0.03 
0.05 
±0.01 
0.05 
±0.02 
0.04 
±0.01 
VE 
(%) 
94.8 
±1.7 
94.1 
±1.2 
95.2 
±1.4 
95.6 
±1.5 
95.1 
±1.2 
96.2 
±1.3 
95.4 
±0.9 
Time to 
voiding 
(min) 
10.2 
±2.4 
11.8 
±1.3 
10.8 
±1.2 
12.2 
±2.2 
11.0 
±0.8 
10.6 
±2.4 
9.2 
±1.7 
Maximum 
IVP 
(mmHg) 
26.6 
±2.2 
30.0 
±2.1 
25.4 
±0.7 
25.6 
±1.5 
26.8 
±0.7 
29.8 
±3.2 
26.8 
±4.1 
 
Veh., vehicle; PVR, post-void residual urine; VE, voiding efficiency; IVP, 
intravesical pressure. Values indicate the mean±SEM of five (ASP6432) or four 
(tamsulosin) animals. There were no statistical differences in any parameters 
between groups (one-way ANOVA). 
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Figure 2-1. Representative traces of urethral perfusion pressure (UPP) in 
anesthetized rats under isovolumetric conditions (A) and changes after 
treatment with vehicle (B), tamsulosin (0.01 mg/kg iv) (C), and ASP6432 (1 
mg/kg iv) (D). 
UPP was measured under urethane anesthesia and isovolumetric conditions. 
Intravesical pressure (IVP) was monitored to confirm that reflex bladder 
contractions and urethral relaxations occur in a synchronized manner. Drugs were 
administered intravenously. Down arrows indicate the timing of administration. 
UPPbase, UPP at the bladder filling phase; UPPnadir, the minimum UPP at the urine 
voiding phase; HFOs, high frequency oscillations. 
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Figure 2-2. Effect of ASP6432 and tamsulosin on urethral perfusion pressure 
(UPP)-related parameters in anesthetized rats under isovolumetric 
conditions. 
The maximum change in UPP at the bladder filling phase (UPPbase) (A), the 
minimum UPP at the urine voiding phase (UPPnadir) (B), the duration of urethral 
relaxation at the urine voiding phase (C), and the duration of high frequency 
oscillations (HFOs) (D) in 15 min after treatment with vehicle (Veh), ASP6432 (0.1 
to 1 mg/kg iv), or tamsulosin (Tam) (0.01 mg/kg iv) were calculated for each animal. 
Each column represents the mean±SEM of eight animals.  
#p<0.05 compared with vehicle (Student’s t-test); *p<0.05, **p<0.01 compared 
with vehicle (Dunnett's test using within subject error). 
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Figure 2-3. Schematic diagram of the experimental protocol (A) and changes 
in cystometric parameters after Nω-nitro-L-arginine methyl ester (L-NAME) 
treatment (B) in conscious rats. 
In (B), changes in post-void residual urine (PVR), voiding efficiency (VE), time to 
voiding, and maximum intravesical pressure (IVP) from baseline after L-NAME 
treatment were calculated for each animal. Each column represents the mean±SEM 
of five (Vehicle for ASP6432) or four (Vehicle for tamsulosin) animals. *p<0.05, 
**p<0.01 compared with baseline (paired t-test). CMG, cystometry; NS, not 
significant; Veh, vehicle.  
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Figure 2-4. Effect of tamsulosin (A) and ASP6432 (B) on voiding dysfunctions 
induced by Nω-nitro-L-arginine methyl ester (L-NAME). 
Changes in post-void residual urine (PVR), voiding efficiency (VE), time to voiding, 
and maximum intravesical pressure (IVP) from baseline after treatment with 
vehicle, ASP6432 (0.3 to 3 mg/kg iv), or tamsulosin (0.003 to 0.01 mg/kg iv) were 
calculated for each animal. Each column represents the mean±SEM of five 
(ASP6432) or four (tamsulosin) animals.  
**p<0.01 compared with vehicle (Dunnett's test using within subject error). 
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Chapter 3: Effect of Lysophosphatidic Acid (LPA) and the Type 1 
LPA Receptor Antagonist ASP6432 on Urinary Frequency: 
Potential for LPA1 antagonism in the Treatment of Bladder 
Overactivity 
 
Introduction 
Maintenance of continence and control of the timing of urination by proper storage 
of urine in the bladder are fundamental to leading a normal personal and social life. 
The micturition center located in the pons and the autonomic nervous system 
cooperatively regulate the normal reservoir function of the bladder. Noradrenaline 
released from sympathetic nerve endings activates 3-adrenoceptors expressed in 
the bladder to distend the detrusor smooth muscle and 1-adrenoceptors to contract 
the urethral smooth muscle (de Groat et al., 2015). 
Dysregulation of bladder urine storage function causes storage symptoms, 
characterized by urgency, urinary frequency, nocturia, or incontinence (Abrams et 
al., 2002). Storage symptoms are commonly observed in patients with LUTS 
associated with BPH. Although patients typically find storage symptoms the most 
bothersome (Chapple et al., 2014), treatment of LUTS associated with BPH tends 
to focus on improving voiding symptoms (slow stream hesitancy, incomplete 
bladder emptying, and terminal dribbling). Alpha1-blockers, currently first-choice 
pharmacotherapies, primarily relax the contractions of the prostatic part of the 
urethra and improve BOO, but do not always sufficiently alleviate storage 
symptoms (van Kerrebroeck et al., 2013). Therefore, an agent that potently 
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improves bladder dysfunction in addition to BOO may be a better treatment option 
for LUTS associated with BPH.  
LPA is a small glycerophospholipid found ubiquitously in vertebrates that 
mediates diverse biological actions demonstrating medicinal relevance (Yung et al., 
2014). In the lower urinary tract, LPA contracts urethral strips isolated from rats, 
and increases intraurethral pressure in rats and dogs via LPA1 (Terakado et al., 2017; 
Terakado et al., 2016). In cultured bladder smooth muscle cells, LPA induces 
contraction (Kropp et al., 1999) and is suggested to mediate stretch-induced cellular 
activation possibly via LPA1, the most prominently expressed LPA receptor subtype 
(Kawashima et al., 2015). To my knowledge, however, no study has yet investigated 
the effect of LPA on bladder function in vivo. In Chapter 1 and 2, I demonstrated 
that LPA1 regulates the contraction and tonus of the prostate and urethra, using the 
potent and selective antagonist ASP6432. However, the effect of ASP6432 on 
bladder function remains to be elucidated. 
To clarify the role of LPA and LPA1 in the regulation of bladder function, I 
examined in this Chapter the effects of LPA and the LPA1 antagonist ASP6432 on 
the micturition reflex in conscious rats using continuous cystometry. In addition, I 
evaluated the effect of ASP6432 on the decrease in micturition interval (MI, a 
cystometry parameter reflective of urinary frequency) induced by the NOS inhibitor 
L-NAME. 
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Materials and Methods 
Test reagents 
ASP6432 (Figure 1-1) was synthesized at Astellas Pharma Inc. (Tokyo, Japan). 
ASP6432 was dissolved and serially diluted either with distilled water containing 
0.025 mol/L NaOH or with saline containing 5% N,N-dimethylformamide. LPA 
(1-linolenoyl-2-hydroxy-sn-glycero-3-phosphate) (Avanti Polar Lipids, Inc., 
Alabaster, AL, USA) was dissolved in saline containing 0.1% BSA. L-NAME 
(Nω-nitro-L-arginine methyl ester hydrochloride) (Sigma-Aldrich, St. Louis, MO, 
USA) was dissolved and diluted in distilled water. 
 
Experimental animals 
All animal experimental procedures were approved by the Institutional Animal Care 
and Use Committee of Astellas Pharma Inc. Astellas Pharma Inc. Tsukuba Research 
Center was awarded Accreditation Status by the AAALAC International. Male 
Wistar rats and female Sprague Dawley rats were purchased from Charles River 
Laboratories Japan Inc. (Kanagawa, Japan). The number of animals per group was 
determined based on the effect size and standard deviation estimated from 
preliminary experiments. 
 
Surgical procedures  
Animals were anesthetized with an intraperitoneal injection of pentobarbital sodium 
(50 mg/kg) and fixed in the supine position. For saline infusion into the bladder and 
measurement of IVP, a midline incision was first made in the abdominal wall, and 
a polyethylene catheter (PE-50; Becton, Dickinson & Co., Franklin Lakes, NJ, 
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USA) was then inserted through a small incision made at the bladder apex and the 
tip was placed inside the bladder dome. For drug administration, a polyethylene 
catheter (PE-50) filled with saline containing sodium heparin was inserted into the 
jugular vein. These catheters were tunneled subcutaneously and anchored to the 
skin of the back of the neck using silk ligatures. To evaluate the effect of LPA and 
the effect of ASP6432 on changes induced by LPA, animals were administered 
ampicillin sodium (20 mg/kg, sc) and housed for another three days with free access 
to food and water in individual cages. To evaluate the effect of ASP6432 on L-
NAME-induced changes, cystometry experiments were conducted on the same day 
as the surgery, after the animals had recovered from the anesthesia in Ballman’s 
cages (Natsume Seisakusho Co., Ltd., Tokyo, Japan). 
 
Cystometry experiments under conscious conditions 
Animals were placed in Ballman’s cages, and saline was continuously infused into 
the bladder through the inserted catheter using an infusion pump (STC-525 or TE-
331, Terumo, Tokyo, Japan; KDS100, Muromachi Kikai Co. Ltd., Tokyo, Japan or 
Neuroscience Inc., Tokyo, Japan) at 4.2 mL/h to induce the micturition reflex. IVP 
was measured using a pressure transducer (TP-400T, Nihon Kohden, Tokyo, Japan) 
connected to a pressure amplifier (AP-601G or AP-621G, Nihon Kohden).  
To evaluate the effect of LPA and ASP6432, female Sprague Dawley rats were 
used. The effect of LPA (1, 5, 10, and 15 mg/kg/h) on bladder parameters was 
evaluated in four groups. Before LPA administration, vehicle for LPA (saline 
containing 0.1% BSA) was intravenously infused at 3 mL/kg/h until the micturition 
reflex was stabilized, and the average MI, maximum IVP, BP, and TP of two 
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consecutive micturition cycles were measured as baseline. After determining 
baseline values, intravenous infusion was switched to LPA and cystometry was 
continued. After the changes by LPA were stabilized, the average MI, max IVP, BP, 
and TP of two consecutive micturition cycles were measured. To evaluate the effect 
of ASP6432, a separate experiment was performed. In animals showing greater than 
a 10% decrease in MI from baseline after LPA (5 mg/kg/h) infusion, ASP6432 (0.3, 
1, 3 and 10 mg/kg) was intravenously injected at the end of each micturition cycle 
with incremental dosing and the effect was evaluated at the next micturition cycle. 
Changes following drug treatment were expressed as a percentage of baseline 
values. 
To evaluate the effects of ASP6432 on L-NAME-induced changes, male Wister 
rats were used. L-NAME (10 mg/kg) was intravenously injected after the 
micturition reflex was stabilized. Animals showing greater than a 10% decrease in 
MI at around 30 min after L-NAME administration were used to evaluate the effect 
of ASP6432. ASP6432 (0.3 or 1 mg/kg) or vehicle (saline with 5% DMF) was 
administered intravenously. Cystometry measurement was continued for another 
30 min, and changes in MI, max IVP, BP and TP were calculated.  
 
Data analysis 
PowerLab and LabChart (ADInstruments Japan, Aichi, Japan) were used to 
collect data. Statistical analyses were performed using SAS software (SAS 
Institute Japan, Tokyo, Japan) or Prism (GraphPad Software, San Diego, CA, 
USA). Results are presented as mean ±SEM. The number of animals per group is 
indicated in either the graph or legend of the respective figure. Paired t-test was 
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used to compare changes before and after drug treatment. One-way analysis of 
variance (ANOVA) or ANOVA followed by Dunnett’s multiple comparisons test 
was used to compare the difference between groups. A p value<0.05 was 
considered statistically significant. 
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Results 
LPA caused bladder overactivity in conscious rats 
Under intravenous infusion of vehicle for LPA (saline containing 0.1% BSA), there 
were no differences in baseline MI, max IVP, BP, or TP between the groups. After 
switching the infusion from vehicle to LPA (1, 5, 10, or 15 mg/kg/h), MI dose-
dependently decreased compared to baseline at 5 mg/kg/h and greater. TP also 
statistically significantly decreased compared to baseline at 10 mg/kg/h. No 
significant changes were observed in BP or max IVP (Figure 3-1). 
 
LPA-induced urinary frequency was reversed by the LPA1 antagonist 
ASP6432 
Based on the above findings, we evaluated the effect of ASP6432 on LPA 
(5 mg/kg/h)-induced cystometric changes. Intravenous infusion of LPA 
significantly decreased MI and TP compared to baseline by 47% and 38%, 
respectively. ASP6432 (0.3 to 10 mg/kg iv) dose-dependently inhibited the LPA-
induced decrease in MI, with statistically significant inhibition observed at doses of 
1 mg/kg and greater compared to the vehicle-treated group (Figure 3-2 and 3-3).  
In contrast, ASP6432 did not inhibit the LPA-induced decrease in TP up to 
10 mg/kg iv. Neither LPA nor ASP6432 had an effect on BP or max IVP (Figure 3-
3). 
 
ASP6432 improved L-NAME-induced urinary frequency 
Intravenous injection of L-NAME (10 mg/kg) significantly decreased MI compared 
to baseline without significant changes in max IVP, BP, or TP (Figure 3-4 and 3-5). 
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Treatment with ASP6432 (0.3 and 1 mg/kg iv) dose-dependently and 
significantly reversed the L-NAME-induced decrease in MI compared to the 
vehicle-treated group (Figure 3-4 and 3-6). ASP6432 had no effect on the other 
cystometric parameters tested (Figure 3-6).  
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Discussion 
In this chapter, I demonstrated that LPA decreased MI and TP in conscious rats, 
and that the LPA1 antagonist ASP6432 inhibited the LPA- and L-NAME-induced 
decreases in MI. Despite recent studies demonstrating a significant role for the 
LPA-LPA1 signaling axis in urethral contraction (Saga et al., 2014; Terakado et al., 
2017)(Terakado et al., 2016), the effect of LPA and LPA1 in the bladder has not 
been clarified in vivo. To my knowledge, this is the first study to show that i) LPA 
causes bladder overactivity characterized by decreases in MI and TP, ii) the LPA1 
antagonist ASP6432 reverses the LPA-induced decrease in MI, and iii) ASP6432 
improves urinary frequency induced by the NOS inhibitor L-NAME. 
In the continuous cystometry study in conscious rats, intravenous infusion 
of LPA decreased MI and TP (Figure 3-1). Although I did not measure the plasma 
LPA concentration, the amount of LPA administered in this study (1 to 
15 mg/kg/h, approximately 0.04 to 0.6 mol/kg/min calculated from the free form 
molecular weight of around 450) appeared to be within the physiological level, 
since blood LPA concentrations range from 0.1 to 10 mol/L (Yung et al., 2014) 
and LPA is rapidly eliminated from the plasma (Salous et al., 2013). Given that 
LPA is a multifactorial bioactive phospholipid (Yung et al., 2014), it is likely that 
these LPA-induced changes result from multiple mechanisms. One simple 
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possible mechanism is that LPA induces contraction of the detrusor smooth 
muscle, since LPA contracts cultured bladder smooth muscle cells (Kropp et al., 
1999). However, intravenous LPA infusion did not significantly increase bladder 
contractility parameters such as BP and max IVP up to 10 mg/kg/h, while MI and 
TP decreased at 10 mg/kg/h or less (Figure 3-1), suggesting a minimal, if any, 
contribution of direct detrusor contraction by LPA. Alternatively, urethral 
contraction by LPA shown in Chapter 1 may have reduced the functional capacity 
of the bladder by causing BOO and accumulating post-void residual urine (PVR) 
in the bladder(Vesely et al., 2003). However, intravenous LPA infusion did not 
increase max IVP (Figure 3-1) indicative of a compensatory increase in bladder 
contractility, suggesting that LPA-induced significant BOO is not the cause of 
decrease in MI, although we did not measure PVR due to technical difficulties 
under the present study conditions. 
Another possible mechanism underlying the LPA-induced decrease in MI 
and TP is the excitation of bladder sensory neurons by LPA. Afferent Aδ-fibers 
transduce normal sensations of bladder filling and C-fibers are activated under 
pathological conditions (Fowler et al., 2008; Yoshimura et al., 2002). Stimulation 
or suppression of these afferent fibers leads to decreases or increases in MI and 
TP, respectively (Du et al., 2007; Nagabukuro et al., 2010; Strittmatter et al., 
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2012). In addition, LPA1 mediates the peripheral LPA-induced activation of 
primary afferent and spinal cord neurons (Elmes et al., 2004; Renback et al., 
2000). Further, LPA1 modulates the activity of the tetrodotoxin-resistant sodium 
channel Nav1.8 in dorsal root ganglion neurons (Pan et al., 2016), which is 
implicated in the activation of C-fibers after chemical irritation of the bladder 
(Yoshimura et al., 2001). These prior studies suggest that activation of LPA1 
expressed in afferent neurons can enhance the sensory signaling from the bladder 
and decrease MI and TP. 
Intravenous administration of the LPA1 antagonist ASP6432 significantly 
but not completely inhibited the LPA-induced decrease in MI (Figure3-2, 3-3), 
indicating that LPA1 plays a major role in the LPA-induced decrease in bladder 
capacity. However, the LPA-induced decrease in TP was not affected by ASP6432 
(Figure 3-3), despite my initial hypothesis. The present study result suggests that 
the LPA-induced decrease in TP is mediated by other LPA receptor subtypes or 
other LPA-binding proteins that regulate sensory signaling. LPA3 and LPA5 
receptors are implicated in the process of allodynia (Murai et al., 2017; Uchida et 
al., 2014), although it is unknown whether there is any mechanistic similarity 
between allodynia and bladder sensation. LPA can directly bind and activate 
transient receptor potential (TPR) channels TRPV1 and TRPA1 (Kittaka et al., 
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2017; Nieto-Posadas et al., 2011), which are expressed in afferent fibers and are 
involved in bladder hypersensitivity by acting as sensors for stretch and/or 
chemical irritation (Andersson, 2016). Direct activation of these channels by LPA 
may activate bladder afferent fibers and contribute to decreasing the TP and MI, 
which were not reversed by ASP6432. Another possibility is that peripherally 
administered LPA acts in the central nervous system (CNS), which ASP6432 
cannot affect due to its low brain permeability (data not shown), although it is 
unknown whether and to what extent LPA penetrates the brain blood barrier. 
Further studies are needed to identify the mechanistic basis of the effect of LPA 
and LPA1 on bladder function, including the mechanism governing the LPA-
induced decrease in TP and its implication for the micturition complex. 
To explore the consequence of suppressing LPA1 on bladder function, I 
evaluated the effect of ASP6432 on urinary frequency elicited by L-NAME in 
conscious rats. Previous studies suggest that L-NAME affects bladder urine 
storage function via multiple mechanisms. Bladder perfusion of L-NAME (10 
mg/mL) enhances the decrease in TP by capsaicin (Caremel et al., 2010) and 
increases the activity of bladder A- and C-fibers in anesthetized rats (Aizawa et 
al., 2011). The intravenous L-NAME administration (20 mg/kg) increases max 
IVP and decreases MI in conscious rats, while MI is increased in anesthetized rats 
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(Masuda et al., 2007). In the present study in conscious rats, intravenous 
administration of L-NAME (10 mg/kg) decreased MI without significantly 
affecting max IVP, BP, or TP (Figure 3-4 and 3-5), which is consistent with 
findings using intraarterial L-NAME administration (10 mg/kg) in conscious rats 
(Persson et al., 1992). Results of the present and previous studies suggest that 
systemic administration of L-NAME at 10 mg/kg decreases MI in conscious rats 
as a result of a combination of minor effects on multiple mechanisms regulating 
the micturition reflex. 
ASP6432 significantly reversed the L-NAME-induced decrease in MI 
(Figure 3-4 and 3-6), indicating that inhibition of LPA1 by ASP6432 can 
ameliorate urinary frequency resulting from impaired NO production. However, to 
my knowledge, no studies have investigated the correlation between impaired NO 
production and LPA1 activation. Given that both L-NAME and ASP6432 altered 
MI without affecting other cystometoric parameters (Figure 3-5 and 3-6), the 
mechanism underlying the effect of ASP6432 on L-NAME-induced decrease in 
MI may be multifactorial, as suggested by the effect of L-NAME at 10 mg/kg iv 
on MI. Another hypothesis is that urethral relaxation by ASP6432 demonstrated in 
Chapter 1 and 2 may have suppressed the sensory signaling from the urethra that 
facilitates bladder contraction (Danziger and Grill, 2017; Yokoyama et al., 2007). 
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However, it is unknown whether and how L-NAME or ASP6432 affects the 
afferent signaling from the urethra and modulates MI. Further investigation is 
required to elucidate the exact mechanism of action of ASP6432 on L-NAME-
induced changes in bladder function. 
The present finding that ASP6432 significantly reversed the LPA- and L-
NAME-induced decreases in MI suggests that ASP6432 has the potential to 
ameliorate urinary frequency and storage symptoms in BPH patients. This 
potential on top of potent urethral relaxation shown in previous chapters may 
provide ASP6432 with a significant advantage over existing pharmacotherapies, 
given that i) patients with symptomatic BPH normally have storage symptoms in 
addition to voiding symptoms (Gacci et al., 2018); ii) 1-blockers, the current 
first-choice pharmacotherapies, do not always satisfactorily improve storage 
symptoms (van Kerrebroeck et al., 2013); and iii) tadalafil, the only approved 
PDE5 inhibitor for the treatment of LUTS associated with BPH, did not 
significantly improve maximum urine flow or PVR in the majority of clinical 
studies(Hatzimouratidis, 2014). Further preclinical and clinical investigations will 
contribute to determining the optimal therapeutic option for treatment of the 
diverse symptoms of LUTS associated with BPH. 
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The present study results provide various insights for further investigations 
into the role of LPA1. Given that our results are limited to rodents, the expression 
and function of LPA and LPA1 should be confirmed in the human bladder, 
particularly in pathological conditions. As mentioned above, detailed investigation 
is required to fully elucidate the exact mechanism of action of LPA1 on MI, and 
the possible involvement of other LPA receptor subtypes or molecular targets on 
the LPA-induced change in TP. In addition, potential interaction between LPA1 
and NO or other neurotransmitters should be clarified. Future studies on these 
aspects will lead to a more extensive characterization of the therapeutic potential 
of ASP6432 in the treatment of lower urinary tract dysfunctions. 
In conclusion, I demonstrated for the first time that LPA is a bioactive 
phospholipid capable of causing bladder overactivity characterized by decreases 
in MI and TP, and that the LPA1 antagonist ASP6432 reversed the LPA- and L-
NAME-induced decreases in MI. The results in this chapter suggest a significant 
role for LPA1 in regulating the functional capacity of the bladder, and the potential 
of ASP6432 as a novel therapy for the treatment of bladder dysfunction caused by 
lower urinary tract diseases like storage symptoms in LUTS associated with BPH. 
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A. 
 
B. 
 
Figure 3-1. Cystometry parameters measured (A) and the effect of 
lysophosphatidic acid (LPA) on cystometric parameters in conscious rats (B). 
Micturition interval, maximum intravesical pressure (IVP), baseline pressure, and 
threshold pressure at baseline and after LPA infusion (1, 5, 10, and 15 mg/kg/h) 
were measured. Each column represents the mean ± SEM of four to six animals. 
* p<0.05, ** p<0.01 vs. baseline (paired t test).  
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Figure 3-3. Effect of ASP6432 on lysophosphatidic acid (LPA)-induced changes 
in cystometric parameters in conscious rats.  
Changes in micturition interval, maximum intravesical pressure (IVP), baseline 
pressure and threshold pressure after ASP6432 or vehicle (distilled water containing 
0.025 mol/L NaOH) administration were measured. Each parameter was expressed 
as a percentage of baseline values. Data are presented as the mean ± SEM of eight 
(ASP6432) or six (vehicle) animals. ## p<0.01 vs. baseline (paired t test), ** p<0.01 
vs. LPA (Dunnett’s test using within subject error).BL, baseline; N.S., not 
significant. 
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Figure 3-5. Effect of Nω-nitro-L-arginine methyl ester (L-NAME) on 
cystometric parameters in conscious rats. 
Micturition interval, maximum intravesical pressure (IVP), baseline pressure, and 
threshold pressure at baseline and after L-NAME administration were measured. 
Each column represents the mean ± SEM of eight animals. 
** p<0.01 vs. control interval (paired t test). 
BL, baseline; N.S., not significant.  
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Figure 3-6. Effect of ASP6432 on the Nω-nitro-L-arginine methyl ester (L-
NAME)-induced decrease in micturition interval (MI) in conscious rats.  
Changes in the micturition interval, maximum intravesical pressure (IVP), baseline 
pressure, and threshold pressure after treatment with L-NAME (10 mg/kg iv) 
followed by ASP6432 (0.3 and 1 mg/kg iv) or vehicle are shown. Each column 
represents the mean ± SEM of five to eight animals. 
** p<0.01 compared to vehicle (Dunnett’s multiple comparisons test). 
BL, baseline; N.S., not significant. 
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General discussion  
LUTS associated with BPH is one of the most common chronic urological 
diseases among elderly men, and the number of patients is expected to increase as 
the average life expectancy and aging population continue to rise (Roehrborn, 
2005). Despite recent progress in medical research, a number of remaining unmet 
needs of current BPH therapies, such as potent relaxation of the bladder outlet 
component, further improvement in storage symptoms, and suppression of stromal 
cell proliferation, indicate that pharmacotherapies for LUTS/BPH require further 
improvement. There is currently no single pharmacotherapeutic agent that 
substantially suppresses the pathological progression of BPH and improves all 
elements of LUTS. Considering the heterogeneous and multifactorial pathological 
nature of LUTS/BPH, novel treatment strategies will have to improve multiple 
pathophysiological features to achieve a significant treatment effect. While this is 
challenging, it is exciting from a drug discovery perspective to identify a 
mechanism that can simultaneously induce more potent urethral relaxation during 
voiding, suppress stromal hyperplasia, and further improve bladder dysfunction 
because such an agent will significantly improve treatment for LUTS/BPH by 
meeting all major unmet needs of current pharmacotherapies. 
The present study investigated the role of LPA, a pleiotropic lipid mediator, 
and its receptor LPA1 in the lower urinary tract by conducting pharmacological 
characterization of the novel LPA1 antagonist ASP6432. It was important and 
necessary to elucidate these characteristics in this study because the exact role of 
the LPA-LPA1 signaling axis in the lower urinary tract including its potential as a 
84 
 
 
therapeutic target remained unclear, particularly in vivo, despite its diverse 
biological actions such as smooth muscle contraction (Saga et al., 2014), cell 
proliferation (Adolfsson et al., 2002), and effects on cultured smooth muscle cells, 
and the potential pathophysiological relevance in BPH (Zeng et al., 2009). 
In Chapter 1, the pharmacological profile of ASP6432 and its effect on 
urethral/prostatic contractile function and prostate cell proliferation were 
characterized. ASP6432 exhibited potent antagonistic activity against human and 
rat LPA1 with selectivity over all other receptors, ion-channels, transporters, and 
enzymes tested (Table 1-1). In isolated rat tissue strips and anesthetized rats, 
ASP6432 concentration/dose-dependently inhibited LPA-induced urethral and 
prostate contractions (Figure 1-3), demonstrating that LPA1 was responsible for 
these actions. Interestingly, ASP6432 decreased the UPP in the absence of 
exogenous LPA stimulation in anesthetized rats, and the maximum reduction was 
greater than that induced by the α1-blocker tamsulosin. The effect of LPA on smooth 
muscle contraction (Figure 1-2), reported LPA concentration in rat plasma (around 
1 mol/L) (Saga et al., 2014), antagonist activity of ASP6432 on rat LPA1 (Table 1-
1), and pharmacokinetic profile of ASP6432 in rats after intravenous administration 
(Table 1-2) support the hypothesis that endogenous LPA constantly activates LPA1 
and plays a significant role in the regulation of urethral tonus, which is suppressed 
by ASP6432, at least in rats. In addition, ASP6432 suppressed LPA-induced 
proliferation of human prostate stroma cells (Figure 1-6). Given that there is 
currently no pharmacotherapy that is simultaneously efficacious for both of these 
components, the present findings indicate that ASP6432 may represent a novel 
therapy with dual mechanisms for improving BOO. More specifically, in the short 
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term, ASP6432 may be more efficacious than α1-blockers for improving voiding 
dysfunction and associated symptoms by potently relaxing the urethra. In the long 
term, ASP6432 may suppress the progression of stromal hyperplasia, which is not 
significantly improved by 5α reductase inhibitors (Marks et al., 1997), although this 
parameter is particularly difficult to examine in a preclinical setting due to the lack 
of appropriate animal models that mimic prostate stromal proliferation observed in 
the human condition (Hieble, 2011). Nevertheless, the findings in Chapter 1 suggest 
a pivotal role for LPA1 in both urethral/prostatic contraction and cell proliferation, 
and the potential of ASP6432 as a novel therapy for LUTS/BPH with a greater 
urethral relaxation effect and possible suppression of stromal hyperplasia. 
One notable finding in Chapter 1 was that ASP6432 significantly reduced 
the UPP (Figure 1-5), suggesting that endogenous LPA activates LPA1 to induce 
contraction of the urethra to contribute to maintaining urethral tonus. However, 
the role of LPA1 in the regulation of urethral tonus during urine voiding, which is 
critical for determining the efficiency of voiding and comparing the treatment 
effect with 1-adrenoceptor antagonists, was unclear. Therefore, in Chapter 2, I 
generated an animal model that mimicked the status of the bladder and urethra 
during bladder filling and at urine voiding, and evaluated the effect of ASP6432 
and tamsulosin on UPPbase and UPPnadir.  
In anesthetized rats under isovolumetric conditions, ASP6432 dose-
dependently decreased UPPbase and UPPnadir. In contrast, the 1-adrenoceptor 
antagonist tamsulosin reduced UPPbase but did not change UPPnadir (Figure 2-2A 
and 2-2B). To my knowledge, this is the first study to show that an LPA1 
antagonist decreases urethral tonus during urine voiding, suggesting a significant 
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role for LPA1 in controlling urethral tonus during urine voiding. The lack of an 
effect by tamsulosin on UPPnadir is consistent with the notion that the sympathetic 
nervous system is active at the filling phase but not at the voiding phase under 
normal conditions (Fowler et al., 2008). This study also suggests that the effect of 
ASP6432 on urethral tonus is not related to 1-adrenoceptor antagonism because 
ASP6432 induced a greater decrease in UPPbase than tamsulosin (Figure 2-2A), 
reduced the UPPnadir (Figure 2-2B), and showed good selectivity in an off-target 
screen that included l receptors (data not shown). While drugs acting on the NO 
pathway reportedly modulate the duration of urethral pressure at the voiding 
phase (Jung et al., 1999; Wibberley et al., 2002), ASP6432 did not alter the 
duration of urethral relaxation or HFOs (Figure 2-2D), suggesting that LPA1 and 
the NO pathway may act differently to modulate UPP. However, further 
investigations into potential interactions between LPA1 and the adrenergic or 
nitrergic pathways are required to clarify the physiological role of LPA1 in the 
lower urinary tract as well as the potential clinical benefits of the combined use of 
ASP6432 and 1-blockers or PDE5 inhibitors.  
To further assess the benefits of antagonizing LPA1 for reducing urethral 
tonus during urine voiding and improving voiding dysfunction, another animal 
model was generated by suppressing the synthesis of NO using L-NAME. This 
model is based on evidence that NO is a neurotransmitter responsible for urethral 
relaxation during urine voiding (de Groat et al., 2015) and L-NAME inhibits 
urethral relaxation at the voiding phase (Bennett et al., 1995; Masuda et al., 2007) 
and increases PVR (Persson et al., 1992). As expected, L-NAME increased PVR 
and decreased VE (Figure 2-3B). ASP6432 dose-dependently suppressed the 
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increase in PVR and the decrease in VE induced by L-NAME (Figure 2-4B). In 
contrast, tamsulosin did not improve the L-NAME-induced changes in PVR or 
VE (Figure 2-4A). The effect of ASP6432 in the L-NAME model confirms a 
significant role for LPA1 in regulating urethral tonus during urine voiding in male 
as well as female animals, which were used for UPP measurements for 
experimental reasons (see Discussion in Chapter 1).  
The present study results suggest that ASP6432 has the potential to improve 
voiding dysfunctions that are not improved by current pharmacotherapies, given 
that pharmacotherapies approved for the treatment of LUTS with BPH are not 
necessarily effective for LUTS associated with other urological disorders. For 
example, the efficacy of α1-blockers for female LUTS has not been established 
(Bae et al., 2005). Voiding dysfunctions associated with impaired urethral 
relaxation demonstrated in mice with targeted deletion of neuronal NO synthesis 
(Burnett et al., 1997) may be another candidate indication. Underactive bladder 
(Chapple et al., 2015), which may be caused by incomplete bladder emptying as a 
result of an imbalance between the bladder and the urethra, is one possible 
example. Potent urethral relaxation by ASP6432 may overcome the limited 
efficacy of currently available drugs for UAB (Andersson, 2017). 
One significant unmet need of current pharmacotherapies for BPH is in the 
improvement of storage symptoms (Chapple et al., 2014; van Kerrebroeck et al., 
2013). Although LPA1 is predominantly expressed in cultured bladder smooth 
cells and is implicated in stretch-induced cellular activation (Kawashima et al., 
2015), the role of LPA and LPA1 in the regulation of bladder function has not been 
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investigated in vivo. In Chapter 3, the effect of LPA and ASP6432 on the 
micturition reflex was evaluated in conscious rats using continuous cystometry. 
Intravenous infusion of LPA caused bladder overactivity, as characterized by 
the decrease in MI and TP (Figure 3-2 and 3-3). ASP6432 inhibited the LPA-
induced decrease in MI in a dose-dependent manner (Figure 3-1 and 3-3). To my 
knowledge, this is the first study to show that LPA is a biological substance 
capable of inducing urinary frequency in vivo via LPA1. Although the detailed 
mechanisms of the LPA-induced decrease in MI via LPA1 have not been clarified, 
the lack of change in BP and max IVP by LPA (Figure 3-3) suggests a minor, if 
any, contribution by LPA-induced bladder smooth muscle contraction (which 
could negatively affect bladder distention) and LPA-induced urethral obstruction 
(which could reduce functional bladder capacity by causing incomplete bladder 
emptying) to the LPA-induced decrease in MI. One possible mechanism 
underlying the LPA-induced decrease in MP and TP is the activation of sensory 
neurons (Elmes et al., 2004; Renback et al., 2000). However, the expression and 
function of LPA1 in bladder afferent neurons has not been closely examined. In 
addition, ASP6432 did not affect the LPA-induced decrease in TP (Figure 3-3), 
suggesting that another LPA receptor subtype or molecular target may be involved 
in the LPA-induced decrease in TP. Further investigation into the modulation of 
the bladder afferent pathway by LPA and its responsible receptor will help unravel 
the mechanism of LPA-induced changes in bladder function. 
To explore the potential of improving urinary frequency by suppressing the 
LPA-LPA1 signaling axis, I examined the effects of ASP6432 on urinary 
frequency induced by L-NAME in conscious rats using continuous cystometry. L-
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NAME treatment decreased MI compared to that at baseline (Figure 3-5), which 
is consistent with a previous finding that L-NAME suppresses the inhibitory effect 
of NO on bladder excitability and induces bladder hyperactivity(Aizawa et al., 
2011; Caremel et al., 2010; Masuda et al., 2007; Persson et al., 1992). ASP6432 
suppressed the L-NAME-induced decrease in micturition frequency (Figure 3-6), 
suggesting that inhibition of LPA1 activity can ameliorate bladder overactivity 
caused by impaired NO production. However, it should be noted that L-NAME 
can also affect bladder functions as a result of inhibiting urethral relaxation during 
voiding (Persson et al., 1992) or suppressing the sensory signaling from the 
urethra that facilitates bladder contraction (Danziger and Grill, 2017; Yokoyama et 
al., 2007), although it is unknown whether L-NAME decreases MI by affecting 
the afferent signaling from the urethra.. That ASP6432 improved the L-NAME-
induced decrease in MI suggests that LPA1 may be involved in bladder 
dysfunction, and that ASP6432 has the potential to improve bladder overactivity 
on top of its potent urethral relaxation effects during voiding and potential 
suppression of prostate stromal hyperplasia. The exact site/mechanism of action of 
LPA1 in the regulation of bladder functions, however, needs further investigation. 
In summary, the present study demonstrated a number of novel findings. In 
vitro experiments confirmed that ASP6432 is a potent and selective LPA1 
antagonist (Table 1-1). Studies using LPA and ASP6432 indicate that LPA1 may 
be responsible for LPA-induced prostate and urethral contraction (Figure 1-3) and 
prostate stromal cell proliferation (Figure 1-6). In vivo studies using LPA and 
ASP6432 further confirmed that LPA1 plays an important role in mediating the 
LPA-induced increase in urethral pressure (Figure 1-4) and urinary frequency 
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(Figure 3-3). In addition, ASP6432 potently decreased the urethral pressure, 
including during urine voiding, to a greater extent than that induced by tamsulosin 
(Figure 1-5, 2-2). Further, ASP6432 prevented voiding dysfunction (Figure 2-4) 
and reversed the decreased micturition frequency induced by L-NAME (Figure 3-
6). These results suggest extensive roles for LPA1 in the regulation of the lower 
urinary tract, ranging from prostate cell proliferation to bladder micturition 
interval, and the potential of ASP6432 in improving BPH and associated LUTS. 
The effects of ASP6432 clearly differentiate it from existing pharmacotherapies, 
such as its potent urethral relaxation effect during urine voiding, improvement of 
bladder function, and the potential suppression of prostate stromal cell 
hyperplasia. 
While the present findings provide various insights for further investigations 
into the role of LPA1, detailed mechanisms underlying the LPA1-mediated 
modulation of the lower urinary tract has not been fully unraveled, including the 
intracellular signaling pathway responsible for controlling smooth muscle 
contraction, interaction between LPA1 and other signaling pathways, the 
mechanism governing the modulation of bladder functions, and the in vivo 
prostate growth inhibition by suppressing LPA1. Future studies on these aspects 
will allow for a more extensive characterization of the therapeutic potential of 
LPA1 antagonists in the treatment of BPH and associated LUTS. In addition to 
urological diseases, ASP6432 may have other indications, given that a number of 
previous studies have demonstrated that LPA1 antagonists are effective in a 
variety of disease models. Findings in other research areas may help researchers 
in urology to better understand the function of LPA1 in the lower urinary tract. 
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In conclusion, the present study results suggest a role for LPA1 in regulating 
the function of the lower urinary tract, and the potential of ASP6432 as a new 
therapeutic option for LUTS associated with BPH and other lower urinary tract 
diseases. 
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